

Advisory Committee Briefing Document  
February 7, 2000

**Medical Officer's Gastroenterology Advisory Committee Briefing  
Document  
Division of Anti-Inflammatory, Analgesic and Ophthalmologic Drug  
Products: HFD-550**

**NDA 20,998: Supplement # 9  
Sponsor: Searle**

**Name of drug: Celecoxib (Celebrex™)**

**Dose 400mg bid**

**Subject of Consult: Review of Celecoxib Long-Term Arthritis Safety  
Study (CLASS)**

**Materials reviewed: Protocols and Study reports for N49-98-02-102 and  
N49-98-02-035**

**Submission date: June 12, 2000**

**Reviewer: Lawrence Goldkind M.D.**

<b>Table of Contents</b>	<b>Page</b>
Background	2
Clinical studies: N49-00-035/N49-00-102	5
Reviewer's comments on objectives	5
Reviewer's comments on study design	9
Reviewer's comments on statistical analysis	14
Conclusions related to changes in statistical analysis	21
Results	23
Conclusions related to GI Endpoints	51
External sources of relevant data	53
Risk factors	54
Overall safety profile	60
Additional potential safety concerns	66
Overall conclusions	67
Appendix: Original protocol and major amendments	69
References	91

## **Background**

Celebrex (C) was approved in 1998 for the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA). The approved dose was 200 to 400 mg daily. In 1999 C was approved for the treatment of Familial Adenomatous Polyposis (FAP) at a dose of 800 mg daily. This product is a highly selective inhibitor of cyclooxygenase-2 (COX-2). The drive to develop highly selective cyclooxygenase (COX) inhibitors was based on the hopes that the safety profile would be improved compared to less selective agents. Upper gastrointestinal ulcers complicated by pain, bleeding and perforation are a labeled complication of NSAIDs. Of the two isoforms, COX-1, a constitutively-generated enzyme has been considered critical to the maintenance of the upper gastrointestinal mucosal integrity. Physiological mechanisms that are linked to "maintenance" effects of COX-1 generated prostaglandins include gastric mucous production, bicarbonate secretion and mucosal blood flow. Inhibition of this enzyme has been linked to the gastrointestinal toxicity of NSAIDs. COX-2 is upregulated in inflammatory conditions. Since the identification of the second isoform of COX, it has been hoped that selective inhibition of this isoform would effectively treat inflammatory conditions and pain with less gastrointestinal toxicity. The original NDA included extensive safety data related to upper gastrointestinal ulceration that are reflected in the product label. C was associated with fewer endoscopically defined (as opposed to symptomatically defined) ulcers compared to ibuprofen and naproxen. The studies submitted to the Division did not however, replicate a difference between C and diclofenac at this specified endpoint. Furthermore, the studies reviewed to date have not differentiated C from other NSAIDs studied in terms of gastrointestinal symptoms and clinically meaningful ulcers. Some GI symptoms appear to be more commonly associated with C compared to the other NSAIDs studied while some were more common in specific comparators.

Comparative safety claims are susceptible to bias by selectively defining the events of interest without incorporating other potentially important toxicities. Comparative study of symptoms and clinically relevant outcomes must be linked to dose and specific comparator. Comparative study of safety and subsequent safety claims are intrinsically different than the well ploughed area of drug efficacy. Efficacy is typically established for a particular beneficial effect. Study can therefore be based on prespecified definitions, objectives, instruments of measurement and statistical analysis. Safety, by comparison is multifaceted and therefore less easily studied and quantified. Specific safety claims other than those associated with ultimate endpoints such as death or permanent disability are difficult to study in an unbiased way that includes the concept of overall safety.

Upper gastrointestinal toxicity has been identified as a major health risk associated with the use of NSAIDs. Some estimates of the number of deaths due to the complications of gastrointestinal bleeding and perforation attributed to these products as a class are in the range of 10-20,000 per year in the United States. Based on these estimates, NSAIDs contain a generic warning of GI risk. Thus, gastrointestinal toxicity appears to be an appropriate specific safety issue for study. COX-2 selective inhibitors hold the promise of having less GI toxicity than less selective agents. Just as relative specificity of COX

## Advisory Committee Briefing Document

February 7, 2000

isoenzyme inhibition exists, so does the possibility of **relative** specificity of GI safety. Available information about the toxicity of NSAIDs suggests that each NSAID most likely has a somewhat unique profile. The study of relative safety has been limited by the difficulties inherent in safety studies compounded by the difficulties in comparative studies of many agents, at different doses, over long periods of time, using different endpoints in heterogeneous populations. The presence of generic products further discourages large expensive comparative studies.

The most daunting challenge in the study of GI safety is that the most important outcomes of bleeding, obstruction and perforation are rare events, estimated to occur in less than several percent of patients on chronic NSAIDs per year. (The estimates of perforations, ulcers and bleeding that appear in the GI warning section of NSAID labels include ulcers associated with pain alone, without the more serious complications). Therefore, large studies are required.

Once the morbid outcomes of bleeding, obstruction and perforation are excluded, it becomes difficult to define an appropriate safety comparison for NSAIDs. The majority of ulcers are painless and up to 30% of patients on NSAIDs experience abdominal pain. The correlation between UGI symptoms and mucosal damage produced by NSAIDs is poor. Gastric adaptation to the effects of NSAIDs has been well described and UGI lesions are frequently transient. This produces new difficult questions. Is abdominal pain less or more significant than other GI symptoms such as diarrhea, nausea or vomiting? Are such symptoms more relevant than other toxicities such as renal or hepatic damage?

The original NDA database suggested that C did **not** differentiate from the three comparators studied (ibuprofen, diclofenac and naproxen) in terms of symptoms nearly as it did for endoscopic ulcers. Based on these findings, the current product label includes the same warnings regarding gastrointestinal toxicity that less selective NSAIDs have. Based on the theoretical advantages of COX selectivity discussed previously and the endoscopic data that appears in the product label, C has been widely accepted as “safer” than previously approved NSAIDs<sup>1</sup>. Although it is tempting to accept the development of asymptomatic ulcers as a meaningful endpoint and a surrogate for clinically relevant outcomes, there is inadequate evidence to date to accept this as fact. The clinical outcome trial entitled, “MUCOSA” published in 1995 in conjunction with other studies of endoscopically defined ulcers associated with the use of NSAIDs and misoprostol are suggestive of a correlation. This study did not have prespecified outcomes and a statistical plan that allowed for firm conclusions. Furthermore, this study cannot be extrapolated to all other potentially “gastroprotective” drugs. Therefore, adequate evidence of a uniquely improved GI safety profile for C was not established in the original NDA.

The Medical Officer’s Consult Review from the Division of Gastrointestinal and Coagulation Drug Products dated December 1998 reflects the view at the time of the original NDA submission that endoscopic ulcers had not been validated as surrogates for clinically meaningful events. The submitted comparative information on endoscopic ulcers was not accepted by the Division at the time of the original NDA submission as

## Advisory Committee Briefing Document

February 7, 2000

adequate to change the NSAID GI warning template on the Celebrex label. The final recommendation of the Consult review dated December 1998 stated that:

“ It is recommended that future studies with well defined and clinically important UGI endpoints be planned to address safety claims related to clinically significant UGI endpoints. These studies and postmarketing experience will be needed to accurately define the relationship between this new molecular entity and the class of drugs currently in use and described as NSAIDs.”

Databases are inadequate at the time of marketing to fully define the safety profile of a new drug. This is particularly true of new molecular entities and drug classes. (Some authors contend that COX-2 selective agents represent a new class. The World Health Organization has placed such agents in a separate class than traditional NSAIDs that are less selective.) The wide acceptance evidenced by many millions of prescriptions in the first year of marketing reflects acceptance of C as a safer alternative to traditional NSAIDs. However, clinically relevant safety endpoints are rare and may be missed in a database of even several thousand subjects. Authors outside the FDA have voiced concern over this as well. The following extensive quote is taken from a lead editorial in the journal *Rheumatology*, September 2000.

“ While it is still true that Cox-1 is expressed constitutionally in most cells and Cox-2 is induced in sites of inflammation and other pathology, recent careful work has clarified several physiological situations in which Cox-2 inhibitors in the clinic are understood only partly at present...

The driving force behind the rapid and forceful cooperation between basic science and drug development was concern about the serious toxicities of conventional NSAIDs and aspirin, not least the increased fatalities resulting from gastrointestinal bleeding and ulcer perforation. Those who are skeptical about extrapolation from databases such as ARAMIS are referred to a Finnish study that identified 30 fatalities from the use of NSAIDs in that country in a single year. Cox-2 is up-regulated in the inflamed joint, and the hypothesis was that selective inhibition of the inducible Cox-2 isoenzyme would offer therapeutic efficacy without this severe toxicity. Endoscopic data from clinical trials support this hypothesis, *but information about the risk of serious events, i.e. bleeding and perforation is still not at hand. New insights into the biologic function of Cox-2 should caution us from the uncritical use of Cox-2 inhibitors. There is a convincing evidence from published trials that celecoxib is equivalent but not superior to conventional NSAIDs in the symptomatic control of osteoarthritis and rheumatoid arthritis. However, long-term safety data can be established only with time and, as with all new types of drugs, we should be vigilant in recognizing possible new types of problems. The questions that must still be addressed concern the ultimate consequences of selective inhibition of Cox-2 and its biological functions”* 1

( italics, reviewer's addition)

## Advisory Committee Briefing Document

February 7, 2000

Another author in a review article in the New England Journal of Medicine stated that:

“ In spite of enthusiasm for these promising new agents NSAIDs, some questions remain regarding their highly selective inhibition of cyclo-oxygenase-2. For example, cyclo-oxygenase-2 might generate endogenous prostanoids that are biologically important....

..although the highly selective cyclo-oxygenase-2 inhibitors offer considerable promise in the treatment of inflammatory arthritides, careful surveillance will be important to determine their ultimate benefit and safety profile.”<sup>2</sup>

The Division and the sponsor have agreed that indirect validation of the surrogacy of endoscopic ulcers for clinically meaningful upper gastrointestinal injury as well as a desire for a larger controlled database for overall safety assessment warranted a large controlled study of clinically relevant safety outcomes. While upper gastrointestinal tract injury was the primary and prespecified endpoint, the sponsor and the Division shared the concerns noted by the author of reference #1.

The primary medical officer's review will assess the overall safety profile generated by the current submission. This GI consult review will deal primarily with the gastrointestinal outcomes from studies 102 and 035.

### **Clinical studies**

#### **N49-00-035/ N49-00-102**

The final protocol and a summary of amendments appear in Appendix I. Reviewer comments related to study design are described below. These studies were identical except for the comparator NSAID employed. The prespecified intent was to compare the combined C groups from the two studies and compare them to the composite of both NSAIDs and subsequently to each individual NSAID.

**Objectives:** In the completed study report the stated primary objective was to compare the incidence of clinically significant UGI events (CSUGIEs) associated with celecoxib 400 mg bid to that associated with ibuprofen 800 mg tid and diclofenac 75 mg bid.

**Reviewer's comments related to objectives**

**A. Dose selection:**

*The choice of dose for celecoxib is twice the labeled dose for rheumatoid arthritis. The dose of diclofenac and ibuprofen are within the commonly used range of each for the treatment of OA and RA. While the NSAID comparators have been in use for years and have well-established dose ranges in practice, celecoxib is a new molecular entity and has a less well established efficacy and dose ranging profile. A successful safety comparison may suggest to consumers that there is room to "push" the dose of a drug with proposed analgesic as well as anti-inflammatory properties. This phenomenon of "dose creep" is particularly relevant in the treatment of pain when currently available therapies leave most patients with some residual pain (absence of total pain relief). The widely held expectation that new COX-2 selective agents will have little to no potential for UGI toxicity requires a robust proof of principle. Comparative safety information therefore will be most meaningful for a high dose of celecoxib.*

*The recent recommendation by the advisory committee for the Division of Oncologic Drug Products for accelerated approval of celecoxib at a dose of 800 mg per day for the treatment of FAP was based on a risk/benefit assessment under the assumption that this high dose of celecoxib would not be associated with a meaningfully higher adverse event profile than the more extensively tested anti-inflammatory doses. Future potential indications (particularly in the area of **disease prevention** where the extent and duration of exposure will be greatly expanded) for selective Cox-2 inhibitors will need to be assessed based on a robust safety database. The safety study of the 800-mg daily dose of C (celecoxib) represents a safety study .*

*The UGI toxicity of NSAIDs is generally believed to be dose related. In the endoscopic studies of celecoxib presented in the original NDA, there was no consistent or convincing evidence of a dose related increase in ulcer rates across the several studies. The studies however were not designed to test this hypothesis.*

**B. Selection of comparators:**

*The original protocol included three NSAIDs (naproxen, ibuprofen and diclofenac). A study result demonstrating a lower rate of CSUGIEs in the celecoxib group compared to three widely prescribed NSAIDs would have been robust evidence of a UGI safety advantage compared to previously approved NSAIDs. The original protocol was amended to include only two comparators. This limits the potential generalizability of results.*

## Advisory Committee Briefing Document

February 7, 2000

### **C. Primary objective:**

*The primary objective in the **final** form of the study report reproduced above suggests that the comparison to NSAIDs as a group was the primary goal. However, this was not the case.*

*“The primary comparison will be the incidence of clinically significant UGI adverse events associated with SC-58635 400 mg BID to that associated with ibuprofen 800 mg TID and **separately** to that associated with diclofenac 75 mg BID... The null hypothesis being tested is that there is no difference in the incidence of clinically significant UGI adverse events between the SC-58635 and **each** of the NSAID groups (ibuprofen and diclofenac.” (protocol dated October 26, 1998: bolding and underling by reviewer)*

*The sample size calculation was based on the pairwise comparison of pooled celecoxib and **each** of the NSAIDs. The clinical importance of statistically significant superiority to each of the comparators was reflected in the statistical plans in the **original protocol**.*

*The Division has considered generalizability to be statistically based. Thus comparisons to each of the NSAID comparators were defined in the original protocol. In order to avoid the statistical pitfall of multiple comparisons, a stepwise approach was prespecified. The protocol stated that the celecoxib groups from the two studies would be pooled for comparison to the pooled NSAID groups first. **Only if there was a statistically significant difference between the pooled celecoxib groups compared to the pooled ibuprofen and diclofenac groups would further comparisons to each NSAID be performed to assess the generalizability of the safety comparison.***

*Demonstration of the consistency of superiority of celecoxib across NSAID comparators would be critical to the generalizability of study results. Superiority to only a single NSAID comparator would not support a proof of principle regarding the UGI safety benefits of a Cox-2 inhibitor. The low overall incidence of CSUGIEs may make comparator-specific statistical significant differences difficult to demonstrate. Similarity in trend however, would be critically important.*

### **D. Definition of endpoint:**

*The definition of CSUGIEs chosen by the sponsor is reproduced in Appendix I. This is a clinically meaningful definition and represents a major advance in the study of UGI toxicity of NSAIDs. Many previous studies of NSAID toxicity including the often-cited MUCOSA<sup>2</sup> trial have failed to rigorously prespecify endpoint events. The sponsor has made a methodological commitment in the current trial to a rigorous study of truly significant UGI adverse events. **Endoscopically defined ulcers** do not independently represent a clinically important event. While symptomatic ulcers are important; the lack of adequate correlation between UGI symptoms and ulcers in subjects on NSAIDs creates a significant artifact when using symptomatic ulcers as the primary endpoint of an outcome study. The sponsor states in the current submission:*

Advisory Committee Briefing Document  
February 7, 2000

*“In addition to the pathologic effects on the GI tract mucosa, NSAIDs also produce GI intolerance, which manifests as nonspecific symptoms such as dyspepsia, abdominal pain, and nausea. Because they often occur in the absence of ulcers or ulcer complications, these symptoms are poor positive predictors of serious GI toxicity.”*

Section 1.2 of Integrated summary of safety, benefit and risks

*A recently published review appearing in the New England Journal of Medicine states:*

*“ At least 10-20% of patients have dyspeptic symptoms during NSAID therapy. However, such symptoms are poorly correlated with the endoscopic appearance and severity of mucosal injury, since up to 40% of persons with endoscopic evidence of erosive gastritis are asymptomatic, and conversely, as many as 50% of patients with dyspepsia have normal-appearing mucosa.”<sup>2</sup>*

*The establishment of a CSUGIE (as defined in Appendix I) as the primary endpoint with the addition of symptomatic ulcers only as a secondary endpoint is a major strength of the current study. The low event rate for CSUGIEs requires a large study population for adequate power.*

*An “alternative” definition was also developed to define a more serious event (see appendix I). This alternative definition required criteria that defined a more serious endpoint by requiring documentation of major blood loss based on hypotension and fall in hemoglobin.*

*OA and RA are felt by some to represent different risk groups for CSUGIEs. There are emerging data to suggest that these conditions may be associated with different risk profiles for a multitude of co-morbid conditions. The inclusion of both populations in the study may therefore allow generalizability of the GI as well as overall safety profiles of the three comparators.*

*In summary:*

- *Choice of celecoxib dose*
- *Duration of study*
- *Multiplicity of comparators*
- *Choice of primary endpoint and definition of such as outlined in Appendix I*
- *Inclusion of both RA and OA patients*
- *Size*

*all establish this study as an important and rigorous evaluation of the UGI safety profile of celecoxib.*

*Based on the size and rigor of the protocol in ascertaining safety information in a controlled setting, this study may also provide valuable information regarding the relative overall safety of celecoxib and the comparator NSAIDs. Other prespecified safety endpoints for analysis included:*

- 1. Laboratory parameters are noted in appendix I. These included potentially important renal function and hematological parameters.*
- 2. Symptomatic ulcers without evidence of perforation bleeding or obstruction*

**Reviewer's comments related to study design:**

*The study was well designed with adequate detail provided for randomization, double-blinding, and appropriately timed follow-up. An optimal study of chronic drug safety involves long term follow-up. The treatment period for this study was defined as up to 52 weeks in protocol 102 and 65 weeks in protocol 035. In order to maximize the chronic safety data obtainable from this study, a minimum of 6 months exposure for all enrolled subjects was included in the protocol, even if the statistically prespecified number of CSUGIEs was reached sooner. The sponsor enhanced the value of this safety study by incorporating this minimum exposure in the protocol.*

*The absence of a screening endoscopy in a study population recently on NSAIDs may allow for the inclusion and therefore incorrect attribution of some ulcers, particularly early in the study. This design however is appropriate for an optimal risk assessment generalizable to clinical settings.*

***Inclusion criteria:***

*The inclusion criteria were broad, including both OA and RA sufferers, both genders and all adult age groups. This is appropriate for a large safety outcome study to be generalized to a large population. Stratification based on type of arthritis may allow disease specific analysis of risk.*

***Exclusion criteria:***

*The exclusion criteria were limited, again adding generalizability to the results. Ethical considerations required the exclusion of subjects with recent active ulcer disease.*

**High- risk populations were otherwise not excluded.**

*A critically important point is the inclusion of subjects on prophylactic low-dose aspirin. This element of the study design may be expected to confound the results of the study by attributing to the Celecoxib group events that may physiologically be attributable to the Cox-1 inhibition provided by aspirin. Subanalysis in a large outcome study may allow*

## Advisory Committee Briefing Document February 7, 2000

*adequate assessment of this potential effect. The benefit of including aspirin- using subjects is critical. Currently 10-20% of Americans use aspirin prophylactically. OA and RA sufferers are enriched populations for aspirin use due to age and age-associated rates of cardiovascular disease. The sponsor has accepted the potential negative impact on the power of the study to detect a difference in event rates between the groups by including aspirin users. The generalizability of results and the safety information related to drug-drug interactions will be very important to a large portion of the population of individuals that uses NSAIDs. Since a history of cardiovascular disease has been considered by many to be an important risk factor for CSUGIEs in general, it is very important that this population be addressed.*

### ***Removal of patients from therapy or assessment:***

*Section 6.2.3 of the protocol describes the reasons for withdrawal. They are all reasonable. Withdrawal due to treatment failure may introduce bias based on informed censoring. This is an unavoidable issue, however.*

*Withdrawal due to adverse sign or symptom is likewise an unavoidable event that may introduce bias. This may be particularly true if subjects with UGI symptoms are at higher risk of developing a CSUGIE and withdraw prematurely. Withdrawal of subjects with ulcers may likewise introduce informed censoring. This is particularly true if one comparator has a higher incidence of UGI symptoms that result in a higher rate of clinically mandated evaluation of symptoms that result in the identification of UGI ulcers that do not meet the definition of a CSUGIE. Bias due to a differential withdrawal due to UGI symptoms would be minimized in the study by including a secondary endpoint of symptomatic ulcers and mandating that all subjects with both severe and less severe GI symptoms (see CSR vol.11 p53) would be evaluated for the etiology of their symptoms.*

*In consultation with the Division, an amendment to the protocols was made that **excluded** from the “primary analysis”, events that occurred within 48 hours after midnight following the first dose of study drug and any event occurring more than 48 hours after midnight after the last dose (unless it occurred within 2 weeks after the last dose of study medication **and** the GEC determined that it was treatment-related. This amendment was generated before the completion of the study and unblinding. It minimized the effect of confounding medications that may be taken during the window periods just before and after the study.*

### ***Treatment period***

*Section 6.4.1.2 of the protocol describes the ascertainment methodology for CSUGIEs as well as symptomatic ulcers. The rigor of ascertainment was adequate and well standardized for CSUGIEs. In addition to monitoring for clinically severe symptoms or signs of perforation, obstruction and bleed, an open ended question was part of each follow-up visit: “Since your last visit, have you experienced or do you currently have any symptoms that are not associated with your arthritis?”*

Advisory Committee Briefing Document  
February 7, 2000

*An element of the overall secondary objective: “Compare the overall safety and tolerability of celecoxib versus ibuprofen and diclofenac;” logically includes other GI adverse events. No formal hypotheses regarding the overall secondary objective or specifically GI adverse events were proposed. A rigorous analysis of such events would be of value. Section 6.4.3.3 notes that; “Upper GI ulcers documented by endoscopy or UGI barium x-ray with no evidence of perforation, bleeding or obstruction were categorized separately” (from CSUGIEs). The systematic approach to monitoring subjects for symptoms and signs of UGI events provided a reasonable and standardized approach to the assessment of symptomatic ulcers. The aggressive approach to monitoring may, however, result in an inflated rate compared to what would be expected in a clinical setting. While the endpoint of symptomatic ulcers may be supportive of the primary endpoint CSUGIEs, this reviewer would be cautious of overinterpretation of this endpoint independently. A post-hoc statistical analysis of the symptomatic ulcer endpoint should be predicated on statistical success at the primary endpoint or establishment of a statistical adjustment to minimize the effects of multiplicity.*

***Statistical methods:***

***The reader is also referred to the statistician’s review.***

*The original hypothesis is discussed on pages 3-5. The statistical analysis in the final study report differs from the original protocol. The analyses in the final report are described in the excerpt below from the completed study report.*

## **8. UGI SAFETY EVALUATION**

For the two end points of primary interest within this section, namely (1) CSUGIEs (traditional definition) and (2) CSUGIEs combined with gastroduodenal ulcers (CSUGIEs/GDUs), the analyses are presented as follows:

- First Six Months of Treatment
  - a. All Patients
  - b. Patients not Taking Aspirin
  - c. Patients Taking Aspirin
- Entire Study Period
  - a. All Patients
  - b. Patients not Taking Aspirin
  - c. Patients Taking Aspirin

The rationale for separately considering the first six months and the entire study period is as follows. Six months of exposure represents a clinically meaningful exposure for a comparison of GI safety end points and can readily be compared to available data from the only prospective, controlled trial published on GI safety end points in patients receiving NSAIDs. (2) Additionally, disproportionate withdrawal of patients with NSAID-associated risk factors was observed over the first six months of the study, and may have artificially decreased the observed rate of clinically significant events in the NSAID groups after six months (i.e., depletion of susceptible patients). The issue of unbalanced withdrawal of patients with NSAID-associated risk factors is discussed further under “Adjustment for Informative Censoring and Risk Factor Analysis” (see Section 8. 6. below).

In addition, the subgroup analyses of patients not taking aspirin and those taking aspirin were performed because of the known confounding effect of aspirin (aspirin use at  $\leq 325$  mg/day was allowed during the study). This effect is established by studies in the literature (10,11), as well as by analyses of risk factors from the present study (Section 8. 6. ), which establish low-dose aspirin as an independent cause of CSUGIEs and ulcers among patients receiving celecoxib.

Advisory Committee Briefing Document  
February 7, 2000

Finally, the reason for presenting combined analyses of CSUGIEs/GDUs is that withdrawal of patients with ulcers that did not meet the prespecified definitions of a CSUGIE removed patients at risk (i.e., an additional source of depletion of susceptible patients). Combining the ulcer and CSUGIE data adjusts for this source of bias. Further confounding due to informative withdrawals resulting from GI adverse events may also have occurred, particularly in the diclofenac group. Differential rates of withdrawal due to GI intolerance are discussed under “Gastrointestinal Effects” (Section 10. 6. 1. ). Statistical considerations relating to informative withdrawal due to GI adverse events and how this may have altered the observed rates of CSUGIEs and gastroduodenal ulcers are discussed under “Adjustment for Informative Censoring and Risk Factor Analysis” in Section 8. 6. .

The analyses of gastroduodenal, gastric, and duodenal ulcers; all reported potential CSUGIEs; all adjudicated potential CSUGIEs; and CSUGIEs analyzed according to the alternate definition were performed similarly to the traditional CSUGIE and CSUGIE/GDU analyses. However, in some cases the six-month analyses and/or the aspirin subgroup analyses are included in appendices and not addressed in the discussion of the results.

CSR p 62-63

**Reviewer's comments on final statistical analysis**

Given the extensive changes made post hoc to the statistical analysis a discussion follows of this reviewer's assessment of the sponsor's justifications for abandoning the original primary and secondary analyses.

- A. Rational for 6-month analysis
- B. Rational for imputation of event rates
- C. Combined analysis of CSUGIEs and GDUs
- D. Analysis based on absence of aspirin use

**A. Rationale for 6-month analysis:**

***The rationale for analyzing the first 6 months as a meaningful endpoint independent of success at the study completion is not convincing.***

- i. A 6-month study period does not reflect the anticipated clinical exposure to drug therapy or the natural history of any of the chronic diseases for which the drug is intended (Osteoarthritis, Rheumatoid Arthritis and Familial Adenomatous Polyposis/FAP). Of note is that at the FDA advisory committee meeting that considered the approval of C for use in FAP the safety profile of C was discussed in the context of required long term exposure and assumed to be superior to other NSAIDs. The surrogate endpoint of fewer polyps was accepted as a basis of accelerated approval of C for FAP with a chronic safety profile assumed to be adequately reflected in the original NDA database. Failure to differentiate from other NSAIDs over longer periods of time is of more importance than similarity over shorter periods if the results are to be truly reflective of risk.***
- ii. The sponsor's rationale for limiting the study period is that the results at the end of the study do not in fact reflect the true risks due to informative censoring that occurred due to an imbalance in the withdrawal rate of the different drugs (related to adverse events). Several points are offered in response.***
  - a. In a naturalistic setting of clinical use such "censoring" will take place and is in fact the setting of most relevance. If one product produces symptoms that result in a higher withdrawal rate that "spares" the occurrence of a CSUGIE, this may result in a study result that does not reflect the "biologic potential" for producing a CSUGIE. It does however reflect what can be anticipated in clinical practice with patients. One may in fact consider self-selected withdrawal from a drug due to a minor adverse event (before experiencing a more severe adverse event such as a CSUGIE) to represent a benefit of the drug's overall adverse event profile compared to a drug that is "silent" in terms of symptoms until a serious adverse event occurs. A literature on this subject exists.<sup>11</sup> Risk of physiologic exposure may in fact be more clinically relevant than exposure in a natural setting (that may be shortened due to intolerance). This discussion is hypothetical but indicates that there are multiple clinically relevant interpretations of a differential withdrawal rate.***

- b. A review of the results (see results section) reveals that the pattern of event rate seen for diclofenac (few late events attributed by the sponsor to the loss of at-risk subjects due to early withdrawal) is also seen in the ibuprofen group despite the similarity in drop out data between C and ibuprofen. The drop out experience identified for the diclofenac group does not explain the nearly identical pattern of events seen in the ibuprofen group.*
- c. Demographic imbalances that potentially avored the diclofenac group were seen in the demographic results. If one were to post-hoc change the statistical analysis, numerous findings in addition to those identified retrospectively by the sponsor may be identified and result in multiple adjustments that undermine the statistical validity of any given analysis.*
- d. The endpoint CSUGIE/GDU to a great extent captures symptomatic patients who have UGI pathology that may put them at high risk for a CSUGIE. This new endpoint represents an internal sensitivity analysis for the potential effects of any bias that may be introduced by differences in withdrawal due to UGI adverse events short of CSUGIEs.*
- e. If the results of the diclofenac group are considered to be biased by the differences in withdrawal rates, limiting the study to 6 months does not address the statistical concern adequately. The pattern of withdrawal actually stabilizes over the later period of the study (see table 39.1 entitled: "Time to withdrawal due to adverse events: review page 16 ). One may choose 3,4 or 5 months to limit the bias. Methods other than post hoc elimination of a large portion of the database would need to be considered. Such approaches however are not necessary and would introduce bias.*

**Reviewer table 1: Abdominal pain causing withdrawal (%)**


	<i>First six months</i>		<i>Entire study period</i>	
	<i>All Subjects</i>	<i>Subjects not on ASA</i>	<i>All subjects</i>	<i>Subjects not on ASA</i>
<i>Celebrex</i>	3.8	3.6	4.3	4.1
<i>Diclofenac</i>	6.1	5.3	6.5	5.8
<i>Ibuprofen</i>	4.5	4.2	4.9	4.7

*Source: sponsor tables 42.1, 42.2, 42.4, 42.5*

*(The results of the study are discussed at greater length later in this review. The sponsor however, defined the final statistical plan with the knowledge that there was a slowing of the event rate at later time points in two of the comparator groups. Sponsor table 14.3 (review page 15) indicates that both the ibuprofen and diclofenac groups had a slowing in event rates over time that was not seen in the C group. The ibuprofen group had a dropout rate and GI AE rate much closer to C than to the diclofenac group. The sponsor does not address this issue. Informative censoring due to a higher rate of early withdrawals due to GI AEs in the diclofenac group does not explain the findings over time in the ibuprofen group. One cannot state from the data available why the event rate for C did not follow the pattern seen in both comparator NSAID groups. It is not surprising that event rates fell towards the end of the study for the NSAID comparators. The risk of CSUGIEs associated with NSAIDs has been thought by some to stabilize over the first few months of treatment. Thus, the slowing of event rates over time does not necessarily suggest that a phenomenon was occurring that required the extreme course of changing the original analysis plan.) Table 10.a displays the exposure by drug and time interval. The prominence of exposure to ibuprofen seen in this table in conjunction with the relatively low withdrawal rates (similar to C) seen in table 10.d and the early occurrence of event rates seen in table 14.3 do not support the sponsor's contention that a bias must be sought for the findings in the life table analysis 14.3.*

*It is plausible that C has a truly higher risk of "late" CSUGIE compared to the "traditional" NSAID comparators.*

Advisory Committee Briefing Document  
February 7, 2000



**Table 10.a. Exposure to Treatment Displayed by Interval: Entire Study Period**

Interval	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
≤3 mo	1202 (30%)	621 (31%)	715 (36%)
>3 to ≤6 mo	467 (12%)	262 (13%)	246 (12%)
>6 to ≤9 mo	291 (7%)	136 (7%)	130 (7%)
>9 to ≤12 mo	1442 (36%)	913 (46%)	415 (21%)
>12 to ≤15 mo	585 (15%)	64 (3%)	477 (24%)
>15 mo	0 (0)	0 (0)	2 (<1%)

Derived from Table T2.4.1. Entries are No. (%) of patients unless otherwise specified.

***B. Rationale for imputation of event rates***

***The sponsor presented data (table 8.n., review page 18) that suggests that there was informative censoring in the withdrawal of subjects due to GI symptoms. This was presented as the basis for imputing event rates as well as performing an analysis of 6-month data. The sponsor's discussion of this issue is reproduced below.***

**10. 2. 3. Adverse Events Causing Withdrawal**

The most common adverse events causing withdrawal ( $\geq 1\%$  in any treatment group) are shown in Table 10.d. Six of the 10 most common events were related to the GI system, five of which represented the most common GI adverse events described above: abdominal pain, dyspepsia, nausea, diarrhea, and flatulence. Three of the events (SGOT increased, SGPT increased, and hepatic function abnormal) were related to elevations in liver function test results, and only led to noteworthy incidences of withdrawals in the diclofenac group. Finally, rash led to withdrawal in more than 1% of patients in the celecoxib and ibuprofen groups, with the highest incidence in the celecoxib group.

The overall incidence of withdrawal due to an adverse event was statistically significantly lower for celecoxib than for diclofenac. Similarly, the differences between celecoxib and diclofenac for three of the GI events (abdominal pain, nausea, and diarrhea) and the three hepatic events (elevations of liver enzyme levels) were statistically significant in favor of

Advisory Committee Briefing Document  
February 7, 2000

celecoxib. Between celecoxib and ibuprofen, the only statistically significant differences were in diarrhea, gastric ulcer, and rash; for gastric ulcer the difference favored celecoxib.

A comparison of Tables 10.b and 10.d shows that of patients experiencing the five most common GI adverse events, approximately 20% to 30% withdrew as a result. These proportions were similar across the treatment groups.


Other statistically significant differences (at  $p \leq 0.05$ ) occurred between groups in less common GI adverse events leading to withdrawal (Table T42.1). Most of these represented events occurring in very few patients: diverticulosis (0.2% for ibuprofen vs 0.0% for celecoxib); eructation (0.4% for diclofenac vs 0.1% for celecoxib); esophagitis (0.7% for ibuprofen vs. 0.2% for celecoxib); and melena (0.3% for diclofenac vs <0.1% for celecoxib).

**Table 10.d. Adverse Events Causing Withdrawal with Incidence  $\geq 1\%$  in Any Treatment Group: Entire Study Period**

Adverse Event	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Any event	22.4	26.5 *	23.0
Abdominal pain	4.3	6.5 *	4.9
Dyspepsia	3.8	4.4	3.9
Rash	2.1	0.7 *	1.3 *
Nausea	1.7	2.8 *	1.8
Diarrhea	1.4	2.7 *	0.8 *
Flatulence	1.2	1.8	1.4
Gastric ulcer	0.3	0.7	1.0 *
SGOT increased	0.1	2.1 *	0.1
SGPT increased	0.1	2.3 *	0.1
Hepatic function abnormal	<0.1	1.1 *	<0.1

Derived from Table T42.1. All numbers are percentages of patients unless otherwise specified.  
\*  $p < 0.05$  vs celecoxib 400 mg BID.

Table T42.4 shows adverse events leading to withdrawal in the first six months of the study. The incidences in this table are in most cases identical to, or slightly below, those in the entire study period, indicating that almost all patients withdrawing due to adverse events did so within six months of beginning the study. This is illustrated graphically in Table T39.1.



**Table 8.n. Risk Calculation for CSUGIEs and CSUGIEs/GDUs in Patients With and Without GI Symptoms**

	No. with Event/Total	Incidence	Relative Risk
<b>CSUGIEs</b>			
With GI symptoms*	18/1483	1.21%	3.9
Without GI symptoms	20/6485	0.31%	
<b>CSUGIEs/GDUs</b>			
With GI symptoms*	62/1483	4.2%	6.3
Without GI symptoms	43/6485	0.7%	

Derived from Appendix 2.4.17.4.

\* Symptoms include moderate to severe abdominal pain, diarrhea, dyspepsia, nausea, or vomiting (the most common GI symptoms).

*The data displayed in the sponsor's tables above do not offer compelling evidence to impute an event rate as proposed or confine analysis to the first 6 months. A CSUGIE/GDU by definition will be associated with a GI symptom.*

*Upon review of the cases of CSUGIEs in the diclofenac, ibuprofen and C groups it becomes clear that many of the GI symptoms used in the sponsor's calculation of relative risk in fact represented the sentinel symptoms of the CSUGIE and are contemporaneous with the events. Thus, the diarrhea seen in the subjects experiencing a CSUGIE was in fact melena caused by an UGI bleed. This is not surprising, as diarrhea is not a symptom pathophysiologically linked to UGI toxicity. It would therefore not be expected to be a premonitory symptom of a CSUGIE or GDU. The abdominal pain reported by the subjects with CSUGIEs was reported within 24-48 hours of the diagnostic evaluation that identified the endpoint event in most cases. Even if a subject in the study withdrew immediately prior to the ascertainment of an event, the follow-up mandated by the study protocol would have ascertained the event and it would have been included in the analysis. The sponsor has not shown that subjects withdrawing due to abdominal pain or diarrhea prior to an event would have been at a higher risk than those remaining in the study.*

*A review of the CSUGIEs database reveals that only 2/38 (5%) of subjects that experienced CSUGIEs had abdominal pain over the month prior to event. This finding is consistent with a body of literature that suggests that complicated NSAID related ulcers are not associated with prior symptoms.<sup>10</sup>*

*Thus the sponsor has not provided adequate support for the hypothesis of informative censoring as well as an adequately justified statistical imputation.*

### **C. Combined analysis of CSUGIEs and GDUs.**

*The inclusion of a combined analysis of CSUGIEs and GDU was a post-hoc decision. Analysis of symptomatic ulcers identified during the study was prespecified as an endpoint of interest in the protocol. This combined analysis produces an endpoint that is most appropriately described as "symptomatic ulcer". The current GI warning on NSAID labels uses the term "PUB (perforation, ulcer, bleed)" to describe the GI events widely described in the medical literature at the time of the development of this section of NSAID labels. This acronym in fact defines a symptomatic ulcer. Such a term does define a clinically relevant endpoint. It represents ulcers identified during an evaluation of patients experiencing symptoms serious enough to warrant physician intervention. Such an event must by definition be relevant to the patient. There are several difficulties with this endpoint as the primary endpoint of study in a controlled trial (aside from the lack of prespecification of this composite endpoint and the attendant issues of statistical multiplicity).*

- a. *Many patients on NSAIDs including C experience UGI symptoms that are consistent with ulcer symptoms that in fact are not related to ulcers. Up to 50% of patients on NSAIDs experience dyspepsia. Up to 15% discontinue therapy due to such symptoms.<sup>2</sup> Only a fraction of these patients have ulcers on UGI endoscopy. Thus, there are a significant number of patients who will have GDUs on endoscopy without causal association to symptoms. The rate of such events would be even higher in a clinical trial where protocol driven ascertainment or bias within the clinical trial setting identifies ulcers that would not be identified in clinical practice. Patients without alarm symptoms on NSAIDs are generally taken off presumed offending medication without any further sequel. Therefore the use of the endpoint PUB in a clinical trial introduces a somewhat artificial entity that does not have the degree of clinical relevance that is inherent in the more clearly defined endpoint, CSUGIE or “POB” (perforation, obstruction or bleed.)*
- b. *Symptomatic ulcers, whether clinically or protocol derived do not represent the same severity of endpoint as a CSUGIE. Only a small fraction of ulcers are thought to result in a clinically serious outcome. In the original NDA database for C the vast majority of ulcers identified were protocol derived and not related to any symptoms. A composite outcome should contain endpoints with similar clinical importance. The correlation between symptomatic ulcers and ulcers that are serious is too weak to consider the two in the same endpoint of a prospective study. The current NSAID warning used the endpoint “PUB” due to the limitation of the available data at the time of conception. This endpoint would not be an appropriate composite endpoint to be studied prospectively. Symptomatic ulcers are so much more common than CSUGIEs that the outcome would be primarily determined by the symptomatic ulcer results and therefore are most accurately defined as such, unless subanalysis of CSUGIEs indicates that this element independently shows a meaningful difference in rates among any chosen comparators. Separate analyses of CSUGIEs and symptomatic ulcers allow for a more meaningful and accurate interpretation of results. The lower rates anticipated for the CSUGIEs reduce statistical power of any trial. If trends are similar for both endpoints and surrogacy is felt to be strongly supported, conclusion about CSUGIEs may be considered based on the totality of evidence from both endpoint analyses.*

#### ***D. Subanalysis based on aspirin use***

*Subanalysis based on aspirin use is appropriate. The lack of prespecification creates problems if the primary hypothesis of the study is not supported by the results. Safety data on C or any NSAID when used with and without concomitant aspirin is clinically important information. If concomitant aspirin negates any benefit of a COX-2 selective*

*agent, public health and health economics have been meaningfully informed. Likewise, additive GI, renal or other systemic risks increased by concomitant use would be vital*

*information for physicians and patients. One strength of this study was in the inclusion of the 20% of otherwise eligible patients who were on aspirin for cardiovascular protection. This issue has been discussed previously in the inclusion criteria review section. Therefore, if statistical adjustment can be made, this subgroup is biologically based and clinically informative.*

### *Summary comments on statistical plan*

1. *The final statistical plan that included the multiple subanalyses reviewed above produces serious multiplicity issues that the sponsor has not addressed. There are 34 comparisons possible based on three comparators and stratification based on study duration, aspirin use and definition of the endpoint of interest (CSUGIE and CSUGIE/GDU). There is good rationale for statistical analysis of subgroups based on the use of aspirin. Statistical adjustment however is necessary due to the multiple comparisons introduced by this analysis.*
2. *The sponsor has not adequately justified the value of an analysis limited to 6-month data nor adequately justified replacing the original analysis with this post hoc analysis. The importance of chronic exposure data to the safety assessment of a drug is noted.*
3. *Analysis of ulcers identified based on symptoms during a clinical trial (PUBs) are anticipated to overestimate such events in practice, however, comparative rates are meaningful. Combining CSUGIEs and the symptomatic GDUs into a single endpoint (PUB) is appropriate and meaningful only if they independently are associated with meaningful comparative results.*
4. *This reviewer considers imputation of an event rate for the diclofenac group based on the analysis presented by the sponsor to be unsupported. The relative risk used for this analysis was based on symptoms that in fact were part of and simultaneous with the outcome event presentation. The imputation method is therefore tautological/circular.*

**Study results:**

*As noted previously, after the study ended the sponsor added a new set of analyses that was based on the first six months of study instead of the entire study period. (This additional analysis is **superimposed** upon a decision to end the study before the prespecified number of CSUGIEs had been reached. The early termination was based on the slowing of the event rate over time and a high cumulative drop out rate. No statistical penalty was applied to the early termination, following discussion with the division, as no interim analysis was performed.)*

**Reviewer's comment:** *The most clinically relevant analysis covers the complete study period as specified in the original protocol. An artificial definition of 6 months is not based on clinical practice in prescribing medications for arthritis. One must assume that chronic therapy will extend beyond 6 months and therefore safety endpoints for the full length of the study are most relevant. The original study period was predefined for statistical reasons. Assumptions regarding statistical significance are based on pre-specification of study period. Therefore, the primary analysis is the analysis considered to be most statistically conclusive. The six-month analysis will be reviewed only as a potentially supportive analysis.*

**Patient Disposition**

*The patient disposition database was reviewed: 386 investigators were recruited in The United States and Canada. Only 4 centers contributed more than one CSUGIE. No site contributed more than 2 events and the enrollment was well distributed among the centers reporting events.*

**Database audit:**

*A review of approximately 50 % of the cases referred to the adjudication committee revealed no CSUGIEs that appeared to be missed. The cases adjudicated as CSUGIEs were well documented. No meaningful differences were identified between the committee's adjudication decisions and this reviewer's assessment based on the pre-specified definition of a CSUGIE.*

**Demographics:**

*Sponsor tables T3, T6, T7, T8 and T10 indicates no significant differences in age, gender, race, history of UGI bleed, GDU (gastroduodenal ulcers), cardiovascular disease and serologic evidence of H. pylori infection (past or current), duration of disease, tobacco use anti-coagulant use, aspirin use and steroid use. Table T7 indicates a potentially meaningful difference in alcohol use. Most of the excess in the diclofenac group was in the category of 1 drink or less per day. This low intake of alcohol is unlikely to create a meaningful impact on the outcome. Alcohol is not considered to be a strong risk factor for CSUGIEs. Sponsor table 25.2 supports this interpretation by revealing an inconsistent relationship between the variable of alcohol intake and CSUGIE outcomes.*

Advisory Committee Briefing Document  
February 7, 2000

Table T25.2  
Risk Factor Analysis of Clinically Significant UGI Events (Medication, Alcohol, and Tobacco Use)

	Intent-to-Treat (ITT) Cohort			----- P-Value (a) ----- Treatment by Factor Interaction	----- Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)		
CORTICOSTEROID USE					
ANY	3/1219( 0.2%)	2/ 568( 0.4%)	2/ 607( 0.3%)	0.954	0.045
NONE	14/2768( 0.5%)	8/1428( 0.6%)	9/1378( 0.7%)		
P-VALUE(b)	0.171	0.503	0.276		
ASPIRIN USE					
ANY	9/ 882( 1.0%)	6/ 445( 1.3%)	1/ 412( 0.2%)	0.020	0.006
NONE	8/3105( 0.3%)	4/1551( 0.3%)	10/1573( 0.6%)		
P-VALUE(b)	0.005	0.010	0.335		
ALCOHOL USE					
ANY	4/1232( 0.3%)	5/ 812( 0.6%)	4/ 386( 1.0%)	0.326	0.605
NONE	13/2753( 0.5%)	5/1184( 0.4%)	7/1599( 0.4%)		
P-VALUE(b)	0.506	0.574	0.166		
TOBACCO USE					
ANY	0/ 628( 0.0%)	2/ 311( 0.6%)	0/ 284( 0.0%)	0.057	0.059
NONE	17/3356( 0.5%)	8/1685( 0.5%)	11/1701( 0.6%)		
P-VALUE(b)	0.993	0.657	0.992		
ANTICOAGULANT USE					
ANY	0/ 42( 0.0%)	0/ 24( 0.0%)	0/ 20( 0.0%)	1.000	0.339
NONE	17/3945( 0.4%)	10/1972( 0.5%)	11/1965( 0.6%)		
P-VALUE(b)	0.993	0.994	0.994		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.

(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Table T 6 suggests a potentially significant difference between diclofenac and the other two comparators in baseline history of GI-related NSAID intolerance. Although a difference of 1.4-1.8% is small, the sponsor has identified a similar differential in withdrawal due to a sponsor-generated definition of GI adverse events as critical to the interpretation of the study. This demographic data may be relevant to the results if NSAID intolerance (independent of a history of CSUGIE/DU) is a risk factor for CSUGIEs.

Advisory Committee Briefing Document  
February 7, 2000

Table T3  
Baseline Demographic Characteristics

	Intent-to-Treat (ITT) Cohort			
	Celecoxib 400 mg BID (N=3987)	Diclofenac 75 mg BID (N=1996)	Ibuprofen 800 mg TID (N=1985)	P-value
AGE (yrs)				0.011 * (a)
N	3987	1996	1985	
Mean	60.6	60.1	59.5	
SD	11.66	11.99	11.93	
Median	61.0	61.0	60.0	
Range	20- 89	21- 90	18- 90	
<= 34	76 ( 1.9%)	52 ( 2.6%)	49 ( 2.5%)	
35 - 44	272 ( 6.8%)	166 ( 8.3%)	172 ( 8.7%)	
45 - 54	881 ( 22.1%)	404 ( 20.2%)	458 ( 23.1%)	
55 - 64	1199 ( 30.1%)	612 ( 30.7%)	582 ( 29.3%)	
65 - 74	1072 ( 26.9%)	526 ( 26.4%)	507 ( 25.5%)	
>= 75	487 ( 12.2%)	236 ( 11.8%)	217 ( 10.9%)	
GENDER				0.064 (b)
Male	1255 ( 31.5%)	650 ( 32.6%)	580 ( 29.2%)	
Female	2732 ( 68.5%)	1346 ( 67.4%)	1405 ( 70.8%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	
RACE/ETHNIC ORIGIN				0.001 *** (b)
Caucasian	3528 ( 88.5%)	1784 ( 89.4%)	1713 ( 86.3%)	
Black	301 ( 7.5%)	151 ( 7.6%)	172 ( 8.7%)	
Asian	29 ( 0.7%)	19 ( 1.0%)	9 ( 0.5%)	
Hispanic	107 ( 2.7%)	36 ( 1.8%)	75 ( 3.8%)	
Other	22 ( 0.6%)	6 ( 0.3%)	16 ( 0.8%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	

Advisory Committee Briefing Document  
February 7, 2000

Table T6  
GI Risk Factors  
Intent-to-Treat (ITT) Cohort

HISTORY OF:	Celecoxib 400 mg BID (N=3987)	Diclofenac 75 mg BID (N=1996)	Ibuprofen 800 mg TID (N=1985)	P-value (a)
<b>UPPER GI BLEEDING</b>				0.655
Yes	68 ( 1.7%)	30 ( 1.5%)	28 ( 1.4%)	
No	3919 ( 98.3%)	1966 ( 98.5%)	1957 ( 98.6%)	
<b>TOTAL</b>	<b>3987 (100.0%)</b>	<b>1996 (100.0%)</b>	<b>1985 (100.0%)</b>	
<b>GASTRODUODENAL ULCER</b>				0.509
Yes	334 ( 8.4%)	170 ( 8.5%)	151 ( 7.6%)	
No	3653 ( 91.6%)	1826 ( 91.5%)	1834 ( 92.4%)	
<b>TOTAL</b>	<b>3987 (100.0%)</b>	<b>1996 (100.0%)</b>	<b>1985 (100.0%)</b>	
<b>GI-RELATED NSAID INTOLERANCE (b)</b>				0.098
Yes	347 ( 8.7%)	202 ( 10.1%)	165 ( 8.3%)	
No	3640 ( 91.3%)	1794 ( 89.9%)	1820 ( 91.7%)	
<b>TOTAL</b>	<b>3987 (100.0%)</b>	<b>1996 (100.0%)</b>	<b>1985 (100.0%)</b>	
<b>CARDIOVASCULAR DISEASE</b>				0.978
Yes	1602 ( 40.2%)	805 ( 40.3%)	794 ( 40.0%)	
No	2384 ( 59.8%)	1190 ( 59.6%)	1190 ( 59.9%)	
<b>TOTAL</b>	<b>3986 (100.0%)</b>	<b>1995 ( 99.9%)</b>	<b>1984 ( 99.9%)</b>	
<b>FLEXSURE FOR H. PYLORI</b>				0.743
Negative	2448 ( 61.4%)	1243 ( 62.3%)	1213 ( 61.1%)	
Positive	1536 ( 38.5%)	752 ( 37.7%)	769 ( 38.7%)	
<b>TOTAL</b>	<b>3984 ( 99.9%)</b>	<b>1995 ( 99.9%)</b>	<b>1982 ( 99.8%)</b>	

*The trend towards higher percentage of enrollees with a history of GI-related NSAID intolerance should be analyzed further. Sponsor table 24.2 suggests that there is a two-fold or greater risk of a CSUGIE in subjects with a history of GI-related NSAID intolerance. The same trend is seen in the outcomes for CSUGIE/GDU displayed in table 24.3 One may consider an adjustment of rates based on the imbalance in baseline demographics for this variable. This would result in a lower rate for the diclofenac group. Such an adjustment is not suggested.*

Advisory Committee Briefing Document  
February 7, 2000

Table T24.2  
Risk Factor Analysis of Clinically Significant UGI Events (GI History)

	Intent-to-Treat (ITT) Cohort						P-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)			Treatment by Factor Interaction		
HISTORY OF UPPER GI BLEEDING								
YES	1/ 68 ( 1.5%)	0/ 30 ( 0.0%)	2/ 28 ( 7.1%)			0.207	0.017	
NO	16/3919 ( 0.4%)	10/1966 ( 0.5%)	9/1957 ( 0.5%)					
P-VALUE (b)	0.144	0.994	<0.001					
HISTORY OF GASTRODUODENAL ULCER								
YES	2/ 334 ( 0.6%)	4/ 170 ( 2.4%)	1/ 151 ( 0.7%)			0.189	0.030	
NO	15/3653 ( 0.4%)	6/1826 ( 0.3%)	10/1834 ( 0.5%)					
P-VALUE (b)	0.509	0.002	0.762					
HISTORY OF UPPER GI BLEEDING OR GASTRODUODENAL ULCER								
YES	2/ 353 ( 0.6%)	4/ 180 ( 2.2%)	2/ 162 ( 1.2%)			0.263	0.012	
NO	15/3634 ( 0.4%)	6/1816 ( 0.3%)	9/1823 ( 0.5%)					
P-VALUE (b)	0.554	0.003	0.183					
HISTORY OF GI-RELATED NSAID INTOLERANCE								
YES	3/ 347 ( 0.9%)	2/ 202 ( 1.0%)	2/ 165 ( 1.2%)			0.993	0.055	
NO	14/3640 ( 0.4%)	8/1794 ( 0.4%)	9/1820 ( 0.5%)					
P-VALUE (b)	0.183	0.272	0.222					
HISTORY OF CARDIOVASCULAR DISEASE								
YES	14/1602 ( 0.9%)	7/ 805 ( 0.9%)	4/ 794 ( 0.5%)			0.036	<0.001	
NO	3/2384 ( 0.1%)	3/1190 ( 0.3%)	7/1190 ( 0.6%)					
P-VALUE (b)	0.002	0.064	0.793					
FLEXSURE FOR H. PYLORI								
POSITIVE	5/1536 ( 0.3%)	5/ 752 ( 0.7%)	7/ 769 ( 0.9%)			0.170	0.385	
NEGATIVE	12/2448 ( 0.5%)	5/1243 ( 0.4%)	4/1213 ( 0.3%)					
P-VALUE (b)	0.460	0.417	0.092					

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.

(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

# Advisory Committee Briefing Document

## February 7, 2000

Table T24.3  
Risk Factor Analysis of Clinically Significant UGI Events or GD Ulcer (GI History) - NSAIDs Pooled

	Intent-to-Treat (ITT) Cohort		P-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	NSAIDs (N = 3981)		
HISTORY OF UPPER GI BLEEDING				
YES	3/ 68 ( 4.4%)	3/ 58 ( 5.2%)	0.751	0.003
NO	40/3919 ( 1.0%)	59/3923 ( 1.5%)		
P-VALUE (b)	0.006	0.019		
HISTORY OF GASTRODUODENAL ULCER				
YES	9/ 334 ( 2.7%)	12/ 321 ( 3.7%)	0.921	<0.001
NO	34/3653 ( 0.9%)	50/3660 ( 1.4%)		
P-VALUE (b)	0.002	<0.001		
HISTORY OF UPPER GI BLEEDING OR GASTRODUODENAL ULCER				
YES	10/ 353 ( 2.8%)	14/ 342 ( 4.1%)	0.999	<0.001
NO	33/3634 ( 0.9%)	48/3639 ( 1.3%)		
P-VALUE (b)	<0.001	<0.001		
HISTORY OF GI-RELATED NSAID INTOLERANCE				
YES	10/ 347 ( 2.9%)	10/ 367 ( 2.7%)	0.348	<0.001
NO	33/3640 ( 0.9%)	52/3614 ( 1.4%)		
P-VALUE (b)	0.001	0.037		
HISTORY OF CARDIOVASCULAR DISEASE				
YES	27/1602 ( 1.7%)	32/1599 ( 2.0%)	0.232	<0.001
NO	16/2384 ( 0.7%)	30/2380 ( 1.3%)		
P-VALUE (b)	0.002	0.048		
FLECKURE FOR H. PYLORI				
POSITIVE	19/1536 ( 1.2%)	34/1521 ( 2.2%)	0.235	0.008
NEGATIVE	24/2448 ( 1.0%)	28/2456 ( 1.1%)		
P-VALUE (b)	0.423	0.005		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.  
(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Table T7  
Baseline Alcohol and Tobacco Use

HISTORY OF:	Intent-to-Treat (ITT) Cohort			P-value (a)	
	Celecoxib 400 mg BID (N=3987)	Diclofenac 75 mg BID (N=1996)	Ibuprofen 800 mg TID (N=1985)		
ALCOHOL USE				<0.001 ***	
None	2753 ( 69.0%)	1184 ( 59.3%)	1599 ( 80.6%)		
Yes (b)	1232 ( 30.9%)	812 ( 40.7%)	386 ( 19.4%)		
1 or Fewer Drinks per Day	1079 ( 27.1%)	712 ( 35.7%)	326 ( 16.4%)		
2-3 Drinks per Day	130 ( 3.3%)	93 ( 4.7%)	46 ( 2.3%)		
4 or More Drinks per Day	11 ( 0.3%)	7 ( 0.4%)	2 ( 0.1%)		
Yes - No Specification	12 ( 0.3%)	0 ( 0.0%)	12 ( 0.6%)		
TOTAL	3985 ( 99.9%)	1996 (100.0%)	1985 (100.0%)		
TOBACCO USE (c)					0.314
None	3356 ( 84.2%)	1685 ( 84.4%)	1701 ( 85.7%)		
Yes (b)	629 ( 15.8%)	311 ( 15.6%)	284 ( 14.3%)		
Level I	198 ( 5.0%)	100 ( 5.0%)	62 ( 3.1%)		
Level II	229 ( 5.7%)	152 ( 7.6%)	75 ( 3.8%)		
Level III	85 ( 2.1%)	59 ( 3.0%)	30 ( 1.5%)		
Yes - No Specification	116 ( 2.9%)	0 ( 0.0%)	117 ( 5.9%)		
TOTAL	3985 ( 99.9%)	1996 (100.0%)	1985 (100.0%)		

Advisory Committee Briefing Document  
February 7, 2000

Table T8  
Arthritis History - Primary Diagnosis  
Intent-to-Treat (ITT) Cohort

	Celecoxib 400 mg BID (N=3987)	Diclofenac 75 mg BID (N=1996)	Ibuprofen 800 mg TID (N=1985)	P-value (a)
OA DURATION (yrs)				0.885
N	2875	1447	1424	
Mean	10.25	10.35	9.94	
SD	9.702	10.330	9.447	
Median	8.00	7.00	7.17	
Range	0.2- 64.0	0.3- 95.0	0.3- 64.0	
RA DURATION (yrs)				0.215
N	1089	543	551	
Mean	11.25	10.47	10.87	
SD	9.859	9.377	9.807	
Median	9.00	8.00	8.00	
Range	0.0- 56.0	0.3- 57.0	0.0- 57.0	

Table T10  
GI Risk Factors - Medication Use  
Intent-to-Treat (ITT) Cohort

	Celecoxib 400 mg BID (N=3987)	Diclofenac 75 mg BID (N=1996)	Ibuprofen 800 mg TID (N=1985)	P-value (a)
CORTICOSTEROID USE				0.357
None	2768 ( 69.4%)	1428 ( 71.5%)	1378 ( 69.4%)	
One Dose to <10% Study Days	413 ( 10.4%)	183 ( 9.2%)	214 ( 10.8%)	
>=10% Study Days	806 ( 20.2%)	385 ( 19.3%)	393 ( 19.8%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	
ANTICOAGULANT USE				0.348
None	3945 ( 98.9%)	1972 ( 98.8%)	1965 ( 99.0%)	
One Dose to <10% Study Days	24 ( 0.6%)	8 ( 0.4%)	8 ( 0.4%)	
>=10% Study Days	18 ( 0.5%)	16 ( 0.8%)	12 ( 0.6%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	
ASPIRIN USE				0.541
None	3105 ( 77.9%)	1551 ( 77.7%)	1573 ( 79.2%)	
One Dose to <10% Study Days	196 ( 4.9%)	104 ( 5.2%)	83 ( 4.2%)	
>=10% Study Days	686 ( 17.2%)	341 ( 17.1%)	329 ( 16.6%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	
ASPIRIN USE DURING FIRST SIX MONTHS				0.198
None	3154 ( 79.1%)	1567 ( 78.5%)	1602 ( 80.7%)	
Any	833 ( 20.9%)	429 ( 21.5%)	383 ( 19.3%)	
TOTAL	3987 (100.0%)	1996 (100.0%)	1985 (100.0%)	


***Conclusion to demographics section:***

- 1. There was an imbalance in the percent of subjects drinking three or fewer alcohol containing beverages per day. This is not expected to impact on the results significantly. Any bias introduced by this imbalance would be expected to result in a slightly higher event rate in the diclofenac group.*
- 2. A higher baseline rate of GI-related NSAID intolerance was seen in the diclofenac group compared to the C and ibuprofen groups. This difference may slightly impact on the withdrawals in this group. It is clear that there are potential confounding variables that are not completely accounted for in the original analysis. It is also clear that selectively choosing which variables to use in imputing rates introduces a bias as well.  
Such potential effects should be considered when assessing the sponsor's proposed imputed event rate for the diclofenac group.*
- 3. There was no meaningful difference in the baseline histories for the other potentially relevant risk factors.*

***Disposition:***

*Sponsor figure 7.b. displays the disposition over the course of the study.*

**Figure 7.b. Disposition of Patients: Entire Study Period**



Derived from Tables T1 and T2.3. Patients counted as completing the study either completed the full scheduled treatment period or remained in the study at the time of study closure.

*Table 10d displays withdrawal rates related to GI adverse events that the sponsor has proposed may be relevant to subsequent risk of CSUGIEs.*

Advisory Committee Briefing Document  
February 7, 2000

**Table 10.d. Adverse Events Causing Withdrawal with Incidence  $\geq 1\%$  in Any Treatment Group: Entire Study Period**

Adverse Event	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Any event	22.4	26.5 *	23.0
Abdominal pain	4.3	6.5 *	4.9
Dyspepsia	3.8	4.4	3.9
Rash	2.1	0.7 *	1.3 *
Nausea	1.7	2.8 *	1.8
Diarrhea	1.4	2.7 *	0.8 *
Flatulence	1.2	1.8	1.4
Gastric ulcer	0.3	0.7	1.0 *
SGOT increased	0.1	2.1 *	0.1
SGPT increased	0.1	2.3 *	0.1
Hepatic function abnormal	<0.1	1.1 *	<0.1

Derived from Table T42.1. All numbers are percentages of patients unless otherwise specified.

\*  $p < 0.05$  vs celecoxib 400 mg BID.

*Tables 37.1, 38.1 and 39.1 suggest a clinically marginal difference overall in drop out rates among the three comparators. These tables in a crude way suggest that the comparators represented appropriate choices for drugs with similar overall tolerability.*

Advisory Committee Briefing Document  
February 7, 2000

Table T97.1  
Time to Withdrawal Due to Lack of Arthritis Efficacy  
Log-Rank Test

Intent-to-Treat (ITT) Cohort






Table T89.1  
Time to Withdrawal Due to Adverse Events  
Log-Rank Test  
Intent-to-Treat (ITT) Cohort



Advisory Committee Briefing Document  
February 7, 2000

Table T38.1  
Time to Withdrawal Due to Lack of Arthritis Efficacy or Adverse Event  
Log-Rank Test

Intent-to-Treat (ITT) Cohort



**Protocol violations:**

**Table 7.a. Distributions of Inclusion/Exclusion Criteria Violation by Treatment Group**

Inclusion/Exclusion Criterion	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Inclusion #2: Negative pregnancy test ≤7 days before first dose	-	1	1
Inclusion #6: Written informed consent prior to study procedures	-	1	-
Exclusion #1: Active malignancy or history of malignancy	5	1	4
Exclusion #3: Active GI disease	2	1	1
Exclusion #4: History of gastroduodenal surgery	6	2	4
Exclusion #5: Clinically significant renal, hepatic, or coagulation dysfunction	-	1	-
Exclusion #6: ALT or AST ≥1.5x ULN or other clinically significant laboratory abnormality	8	5	6
Exclusion #7: Positive fecal occult blood test at screening	15	3	5
Exclusion #8: Hypersensitivity to sulfonamides, COX-2 inhibitors, diclofenac, or ibuprofen	10	6	7
Exclusion #10: Enrollment in prior celecoxib study	1	1	1

Derived from Appendices 4.1.1 and 4.1.2. Entries are numbers of patients.

*When normalized for enrollment numbers, there were no significant differences in withdrawal due to inclusion/exclusion criterion violation.*

**GI ENDPOINT RESULTS**

*The sponsor submitted multiple analyses in the CSR that are listed below. Given the existence of prespecified analyses that identified a primary endpoint success (statistical superiority of C over the combined NSAID comparators and subsequent statistical comparison of C to each individual NSAID comparator at the end of the study period): meaningful interpretation of additional statistical analyses is difficult without statistical adjustment. Any possible meaningful additional analysis requires acceptance of a rationale for the analysis and a statistical correction. This issue was discussed previously in this review within the section on statistical methods. The following analyses will be reviewed.*

1. *Primary prespecified analysis: CSUGIE (traditional definition), entire ITT as well as subgroups based on low dose aspirin ( $\geq 325$ mg/day) use for the entire study period*
2. *Primary prespecified analysis: CSUGIE (alternate definition), entire ITT as well as subgroups based on low dose aspirin ( $\geq 325$ mg/day) use for the entire study period*
3. *Secondary analysis: CSUGIE/GDU, entire ITT as well as subgroups based on low dose aspirin ( $\geq 325$ mg/day) use for the entire study period*

**CSUGIE Results:**

The reader is referred to appendix I for the definition of CSUGIEs and the methods of ascertainment of CSUGIEs and GDUs.

**Table 8.f. Summary of CSUGIE Incidence: Traditional Definitions - Entire Study Period**

	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID	Log-Rank P Values for Celecoxib Vs:		
				Diclo	Ibu	Both
<b>All Patients</b>						
	n=3987	n=1996	n=1985			
No. of CSUGIEs						
Uncensored	17	10	11			
Censored	3	1	2			
Total	20	11	13			
Week 52 crude rate†	0.43%	0.50%	0.55%	0.640	0.414	0.450
No. per 100 pt-yrs†	0.73	0.93	0.98			
<b>Patients not Taking Aspirin</b>						
	n=3105	n=1551	n=1573			
No. of CSUGIEs						
Uncensored	8	4	10			
Censored	1	0	1			
Total	9	4	11			
Week 52 crude rate†	0.26%	0.26%	0.64%	0.972	0.037	0.185
No. per 100 pt-yrs†	0.44	0.48	1.14			

Derived from Tables T14.1 through T15.3.

† Censoring rule applied.

Advisory Committee Briefing Document  
February 7, 2000

**Table 8.e. Distributions of CSUGIEs by Category: Traditional Definitions - Entire Study Period**

<b>Event Category</b>	<b>Celecoxib 400 mg BID (n=3987)</b>	<b>Diclofenac 75 mg BID (n=1996)</b>	<b>Ibuprofen 800 mg TID (n=1985)</b>
<b>UGI Bleeding (Category 1)</b>			
1A: Hematemesis with ulcer/large erosion	1	-	-
1B: Ulcer/large erosion with evidence of bleeding	8	4	7
1C: Melena with ulcer/large erosion	5 *	4	3 *
1D-1: Hemoccult-positive stool with ulcer/large erosion and hematocrit/hemoglobin drop	3 †	2	3
1D-2: Hemoccult-positive stool with ulcer/large erosion and orthostasis	-	-	-
1D-3: Hemoccult-positive stool with ulcer/large erosion and transfusion	-	-	-
1D-4: Hemoccult-positive stool with ulcer/large erosion and blood in stomach	-	-	-
<b>UGI Perforation (Category 2)</b>	1	1 †	-
<b>Gastric Outlet Obstruction (Category 3)</b>	2	-	-
<b>Total</b>	<b>20</b>	<b>11</b>	<b>13</b>
<b>Total Uncensored</b>	<b>17</b>	<b>10</b>	<b>11</b>

Derived from Table T16 and Appendix 2.6.1. Entries are numbers of patients. See Section 6. 4. 3. 1. for full definitions.

\* Two of these events censored from primary analysis. † One of these events censored.

# Advisory Committee Briefing Document

## February 7, 2000

Table T14.3  
Time to Clinically Significant UGI Events - Traditional Definition  
Entire Study Period  
Log-Rank Test with Censoring Rules Applied





Table T15.3  
Time to Clinically Significant UGI Events - Traditional Definition  
Entire Study Period - Patients not Taking Aspirin  
Log-Rank Test with Censoring Rules Applied



*Table 8.f. indicates that there is no statistically significant difference between Celebrex and the NSAID group at the primary prespecified endpoint: Celebrex vs. NSAIDs combined for the entire study period, all subjects ITT population.*

*If one were to bypass the statistical hierarchy and compare Celebrex to each NSAID separately, the 52-week rate suggests a trend in favor of ibuprofen (22% reduction in CSUGIE rate) that may be clinically meaningful if validated. The trend in favor of diclofenac (14% reduction in CSUGIE rate) would be of less clear clinical meaning if validated.*

*Table 14.3 displays the events over time. There is a relatively steady event rate seen in the C group while both ibuprofen and diclofenac display a slowing in the rate of accrual of events over time. This table suggests that long term there may be a higher event rate associated with the use of C compared to the other two comparators. The similarity in pattern seen for both ibuprofen and diclofenac do not support the sponsor's imputation of a higher rate for the diclofenac group based on a higher withdrawal rate due to GI AEs. The ibuprofen group experienced the same drop off in event rates even before 6 months without any difference compared to C in withdrawal due to GI AEs. The same pattern is seen in table 15.3, which displays the time to event for the subgroup of subjects not taking aspirin. This trend is worrisome.*

*As noted earlier in this review, the inclusion of aspirin users in this study was encouraged by the Agency. Important safety information has been collected in a large extended use outcome study that approximates the anticipated population of patients who may be exposed to C. Therefore further analysis is appropriate based on the known biologic effects of aspirin on the UGI tract. It was anticipated from the outset that 10-20% of subjects would be on low dose aspirin and confound the outcome in those subjects. Therefore, it is clinically relevant to consider the results in subjects on aspirin and not on aspirin. The results of such a subanalysis reveals no statistically significant difference between Celebrex and the NSAID comparators combined, which was the prespecified comparison. A further subanalysis by individual NSAID reveals no trend for C versus diclofenac and a strong nominal trend for the C versus ibuprofen comparison. The p-value of .037 is uncorrected for multiple comparisons.*

*If validated, these results would be of little support for a generalizable statement regarding the safety advantage of Celebrex over traditional NSAIDs as a class. Such validation would confirm current opinion that there is a spectrum of GI toxicity among NSAIDs. It would place C within this spectrum rather than distinctly outside the spectrum. This statement has profound impact on the interpretation of safety comparisons*

## Advisory Committee Briefing Document

February 7, 2000

*of other COX-2 agents as well. Choice of a more toxic comparator for a GI safety study may not be used to extrapolate to the universe of “traditional” less selective COX inhibitors (NSAIDs).*

*Sponsor table 8.e. displays the results by type of CSUGIE. These results corroborate the clinical predominance of bleeding in the toxicity of NSAIDs in the upper GI tract. These results also identify within a well-controlled study the most common presentations for such bleeding events. The general presentation of CSUGIEs in the C group was similar to that seen in the traditional NSAID group.*

### **CSUGIE/GDU Results**

*Sponsor table 8.k. displays the results of an analysis that was not prespecified: the event commonly referred to as a “PUB”. This endpoint is discussed earlier in this review and does represent a clinically relevant endpoint. One would expect that trends would be similar between this endpoint and the more rigorous endpoint of CSUGIEs. While the surrogacy of ulcers in relation to CSUGIEs has not been fully validated, a trend was suggested in the original NDA database submitted in 1998. The MUCOSA trial<sup>5</sup> ( a trial assessing the impact of misoprostol on the rate of PUBs) also suggests a correlation between rates of endoscopic ulcers and rates of CSUGIEs for NSAIDs as a group when bridged to endoscopic trials that evaluated the impact of misoprostol on the rates of asymptomatic endoscopic ulcers.*

*Overall, the trends are similar in this analysis compared to the clinically more significant endpoints of CSUGIE (traditional). There is a strong trend in favor of C compared to ibuprofen in subjects not taking aspirin with no trend between C compared to diclofenac. In fact the results show a nominally lower CSUGIE/GDU rate in the diclofenac group compared to C in subjects not taking concomitant aspirin.*

*As discussed previously in this review, the CSUGIE/GDU analysis informs the interpretation of the sponsor’s post hoc imputation of event rates for the diclofenac group based on a high drop out rate for GI adverse events. The protocol mandated that clinically relevant symptoms be evaluated in the study patients. Those episodes of symptoms severe enough to warrant withdrawal should have, to a great extent been referred for evaluation. UGI mucosal lesions (ulcers) that may be interpreted as relevant to future risk of a CSUGIE would have been ascertained and thus have been reflected in the CSUGIE/GDU data (PUB). The CSUGIE/GDU results should be relatively free of potential bias related to inform censoring based on withdrawal due to GI-related adverse events. The lack of significant differentiation between diclofenac and C in this endpoint is consistent with the primary endpoint analysis ( CSUGIE for the entire study period) and argues strongly against the sponsor’s claim of informative censoring driving the negative results vis a vis the diclofenac-C comparisons. The results of the comparison between C and ibuprofen also support the primary analysis.*

Advisory Committee Briefing Document  
February 7, 2000

**Table 8.k. Summary of CSUGIE/GDU Incidence: Traditional Definitions - Entire Study Period**

	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID	Log-Rank P Values for Celecoxib Vs: Diclofenac      Ibu		
<b>All Patients</b>						
	n=3987	n=1996	n=1985			
No. of CSUGIEs/GDUs						
Uncensored	43	26	36			
Censored	3	1	2			
Total	46	27	38			
Week 52 crude rate†	1.05%	1.30%	1.76%	0.296	0.017	0.040
No. per 100 pt-yrs†	1.85	2.41	3.21			
<b>Patients not Taking Aspirin</b>						
	n=3105	n=1551	n=1573			
No. of CSUGIEs/GDUs						
Uncensored	21	10	28			
Censored	1	0	1			
Total	22	10	29			
Week 52 crude rate†	0.68%	0.64%	1.72%	0.992	<0.001	0.020
No. per 100 pt-yrs†	1.16	1.19	3.20			

Derived from Tables T20.1 through T21.3.

† Censoring rule applied.

**Table 8.j. Distributions of CSUGIEs/GDUs by Category: Traditional Definitions - Entire Study Period**

Event Category	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
<b>UGI Bleeding (Category 1)</b>			
1A: Hematemesis with ulcer/large erosion	1	-	-
1B: Ulcer/large erosion with evidence of bleeding	8	4	7
1C: Melena with ulcer/large erosion	5 *	4	3 *
1D-1: Hemoccult-positive stool with ulcer/large erosion and hematocrit/hemoglobin drop	3 †	2	3
1D-2: Hemoccult-positive stool with ulcer/large erosion and orthostasis	-	-	-
1D-3: Hemoccult-positive stool with ulcer/large erosion and transfusion	-	-	-
1D-4: Hemoccult-positive stool with ulcer/large erosion and blood in stomach	-	-	-
<b>UGI Perforation (Category 2)</b>	1	1 †	-
<b>Gastric Outlet Obstruction (Category 3)</b>	2	-	-
<b>Symptomatic Ulcers</b>			
Gastroduodenal‡	26	16	25
Gastric	18	13	22
Duodenal	10	5	3
<b>Total</b>	<b>46</b>	<b>27</b>	<b>38</b>
<b>Total Uncensored</b>	<b>43</b>	<b>26</b>	<b>36</b>


Derived from Tables T22, T23.1 through T23.3 and Appendix 2.6.1. Entries are numbers of patients. See Section 6. 4. 3. 1. for full definitions.


\* Two of these events censored from primary analysis. † One of these events censored.

‡ Any patient with both gastric and duodenal ulcers is counted once in the "Gastroduodenal" row.

Advisory Committee Briefing Document  
 February 7, 2000

Table T20.3  
 Time to Gastrointestinal Ulcer, Bleeding, Perforation, or Obstruction  
 Entire Study Period  
 Log-Rank Test with Censoring Rules Applied





**CSUGIEs in aspirin users:**

Although the primary hypothesis of this study and the biologic rationale for the use of COX-2 selective agents is to avoid the GI toxicity of traditional NSAIDs, there is a lack of scientific data to guide the use of cardioprotective doses of aspirin in patients requiring NSAIDs. One may expect additive toxicity from combined use of aspirin and NSAIDs. Given the reversible platelet inhibition associated with less selective COX inhibitors, some physicians may recommend only an NSAID in subjects who require such therapy in addition to being candidates for aspirin prophylaxis. The inclusion of aspirin users in this study has generated one of the best-controlled databases with which to address this issue.

Appendix 2.5.8 indicates that the use of aspirin increases the event rate in the C group to the range of diclofenac plus aspirin. Thus, there would be no GI safety rationale to the use of low dose aspirin plus C instead of diclofenac plus an aspirin. The results in the

Advisory Committee Briefing Document  
February 7, 2000

*ibuprofen group are somewhat surprising. The event rate is substantially lower with concomitant use of ibuprofen and aspirin use compared with ibuprofen alone. This is counter intuitive. One may suggest that the small numbers of events over time yield statistically meaningless results (see appendix 2.5.11).*

*However, the results of CSUGIEs/GDU (PUBs) stratified by aspirin use also reveals a loss of any benefit with the concomitant use of low dose aspirin. The same pattern of greater risk in the C and diclofenac groups compared to the ibuprofen group is seen in this endpoint as well as the CSUGIE endpoint. There appears to be a higher risk of concomitant ibuprofen and aspirin use than C and aspirin use (see appendix 2.5.12) Furthermore, a secondary endpoint, rates of reported potential CSUGIEs, suggested that clinical suggestive UGI presentations were similar in all groups with concomitant aspirin use. Thus it appears that tolerability as well as clinically serious UGI events is not better in patients taking C compared to both traditional NSAIDs in aspirin users. The current label for C, based on the endoscopic studies in the original NDA database, suggests that aspirin use in conjunction with C may still be “safer” than traditional NSAIDs. This statement should be revisited in light of this new more robust data.*

Appendix 2.5.8  
Clinically Significant UGI Event Rates by Time Interval - Traditional Definition  
Entire Study Period - Patients Taking Aspirin  
Crude and Kaplan-Meier Cumulative Event Rates

Dosing Interval	Intent-to-Treat (ITT) Cohort					
	Celecoxib 400 mg BID (N = 882)		Diclofenac 75 mg BID (N = 445)		Ibuprofen 800 mg TID (N = 412)	
	Censoring Rule Applied	Censoring Rule Not Applied	Censoring Rule Applied	Censoring Rule Not Applied	Censoring Rule Applied	Censoring Rule Not Applied
<b>Crude Rates</b>						
WEEK 1 (1 - 7)	0.00%	0.00%	0.22%	0.22%	0.00%	0.24%
WEEK 4 (8 - 28)	0.11%	0.11%	0.45%	0.45%	0.00%	0.24%
WEEK 13 (29 - 91)	0.34%	0.45%	0.90%	0.90%	0.00%	0.24%
WEEK 26 (92 - 182)	0.68%	0.79%	1.12%	1.12%	0.24%	0.49%
WEEK 39 (183 - 273)	0.79%	1.02%	1.35%	1.35%	0.24%	0.49%
WEEK 52 (274 - 364)	1.02%	1.25%	1.35%	1.57%	0.24%	0.49%
<b>Kaplan-Meier Rates</b>						
WEEK 1 (1 - 7)	0.05%	0.05%	0.23%	0.23%	0.02%	0.26%
WEEK 4 (8 - 28)	0.15%	0.18%	0.59%	0.59%	0.07%	0.31%
WEEK 13 (29 - 91)	0.50%	0.64%	1.30%	1.30%	0.22%	0.46%
WEEK 26 (92 - 182)	1.03%	1.16%	1.60%	1.60%	0.41%	0.65%
WEEK 39 (183 - 273)	1.33%	1.66%	1.80%	2.22%	-----	-----
WEEK 52 (274 - 364)	1.60%	1.93%	-----	2.31%	-----	-----

Note: Kaplan-Meier rates are based on the Highest Kaplan-Meier estimates within that time interval. Uncensored events were defined as those meeting either of the following two conditions: 1. Occurred after 48 hours past midnight of the first dosing day and before 48 hours following midnight of the last dosing day. 2. Occurred after 48 hours past midnight of the last dosing day and before 2 weeks following midnight of the last dosing day and were determined to be causally related to study drug by the GI events committee. Events were censored if they failed to meet either of these two conditions.

Advisory Committee Briefing Document  
February 7, 2000

Appendix 2.S.12  
Gastrointestinal Ulcer, Bleeding, Perforation, or Obstruction Rates by Time Interval  
Entire Study Period - Patients Taking Aspirin  
Crude and Kaplan-Meier Cumulative Event Rates

Dosing Interval	Intent-to-Treat (ITT) Cohort					
	Celecoxib 400 mg BID (N = 882)		Diclofenac 75 mg BID (N = 445)		Ibuprofen 800 mg TID (N = 412)	
	Censoring Rule Applied	Censoring Rule Not Applied	Censoring Rule Applied	Censoring Rule Not Applied	Censoring Rule Applied	Censoring Rule Not Applied
<b>Crude Rates</b>						
WEEK 1 (1 - 7)	0.00%	0.00%	0.22%	0.22%	0.00%	0.24%
WEEK 4 (8 - 28)	0.34%	0.34%	0.45%	0.45%	0.00%	0.24%
WEEK 13 (29 - 91)	1.13%	1.25%	1.35%	1.35%	0.97%	1.21%
WEEK 26 (92 - 182)	1.59%	1.70%	2.47%	2.47%	1.46%	1.70%
WEEK 39 (183 - 273)	1.70%	1.93%	3.60%	3.60%	1.46%	1.70%
WEEK 52 (274 - 364)	2.38%	2.61%	3.60%	3.82%	1.94%	2.18%
<b>Kaplan-Meier Rates</b>						
WEEK 1 (1 - 7)	0.05%	0.05%	0.23%	0.23%	0.04%	0.28%
WEEK 4 (8 - 28)	0.47%	0.47%	0.62%	0.62%	0.17%	0.40%
WEEK 13 (29 - 91)	1.37%	1.51%	1.87%	1.87%	1.40%	1.64%
WEEK 26 (92 - 182)	2.10%	2.24%	3.48%	3.48%	2.09%	2.33%
WEEK 39 (183 - 273)	2.41%	2.73%	5.31%	5.68%	2.48%	2.72%
WEEK 52 (274 - 364)	4.94%	5.26%	-----	5.80%	3.33%	3.56%

Note: Kaplan-Meier rates are based on the highest Kaplan-Meier estimates within that time interval.  
Uncensored events were defined as those meeting either of the following two conditions: 1. Occurred after 48 hours past midnight of the first dosing day and before 48 hours following midnight of the last dosing day. 2. Occurred after 48 hours past midnight of the last dosing day and before 2 weeks following midnight of the last dosing day and were determined to be causally related to study drug by the GI events committee. Events were censored if they failed to meet either of these two conditions.

Advisory Committee Briefing Document  
February 7, 2000

Appendix 2.5.17  
Rates of Reported Potential CSUGIES by Time Interval  
First Six Months - Patients Taking Aspirin  
Crude and Kaplan-Meier Cumulative Event Rates

Intent-to-Treat (ITT) Cohort			
	Celecoxib 400 mg BID (N = 833)	Diclofenac 75 mg BID (N = 429)	Ibuprofen 800 mg TID (N = 383)
Dosing Interval	Event Rate	Event Rate	Event Rate
<b>Crude Rates</b>			
WEEK 1 (1 - 7)	3.00%	3.50%	2.87%
WEEK 4 (8 - 28)	6.60%	6.76%	8.36%
WEEK 13 (29 - 91)	13.33%	13.52%	15.93%
WEEK 26 (92 - 182)	16.65%	18.18%	18.54%
<b>Kaplan-Meier Rates</b>			
WEEK 1 (1 - 7)	3.04%	3.55%	3.43%
WEEK 4 (8 - 28)	6.83%	7.53%	8.66%
WEEK 13 (29 - 91)	14.81%	15.62%	17.94%
WEEK 26 (92 - 182)	19.25%	21.71%	21.89%

Note: Kaplan-Meier rates are based on the highest Kaplan-Meier estimates within that time interval.

**Alternate definition results**

The definition of the “alternate definition” may be found in Appendix I. This definition required a more serious bleeding event than the traditional definition. Given the lack of effect of C on platelet aggregation, one may expect a stronger nominal trend in favor of C in such an analysis

The trends seen in sponsor’s table 8.v. and 8.u. are not supportive of the hypothesis that C is associated with a lower rate of **bleeding** CSUGIEs than either ibuprofen or diclofenac.

**Table 8.v Summary of CSUGIE Incidence: Alternate Definitions - Entire Study Period**

	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
No. of CSUGIEs			
Uncensored	17	5	9
Censored	2	1	1
Total	19	6	10
Week 52 crude rate†	0.43%	0.25%	0.45%

Derived from Tables T30.1 and T30.2.

† Censoring rule applied.

**Table 8.u. Distributions of CSUGIEs by Category: Alternate Definitions - Entire Study Period**

Event Category	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
<b>UGI Bleeding (Category 1)</b>			
1E: Hematemesis with ulcer/large erosion and either hemoglobin drop or hypotension	1	-	-
1F: Ulcer/large erosion with evidence of bleeding and either hemoglobin drop or hypotension	8	2	6
1G: Melena with ulcer/large erosion and either hemoglobin drop or hypotension	5 *	2	2 †
1H: Hemocult-positive stool with ulcer/large erosion and either hemoglobin drop or hypotension	2	1	2
<b>UGI Perforation (Category 2)</b>	1	1 †	-
<b>Gastric Outlet Obstruction (Category 3)</b>	2	-	-
<b>Total</b>	<b>19</b>	<b>6</b>	<b>10</b>
<b>Total Uncensored</b>	<b>17</b>	<b>5</b>	<b>9</b>

Derived from Table T16 and Table T30.1. Entries are numbers of patients. See Section 6. 4. 3. 1. for full definitions.

\* Two of these events censored from primary analysis.

† One of these events censored.

***Analyses not reviewed:***

*The sponsor has presented results of annualized rates of CSUGIEs and CSUGIE/GDU based on the first 6 months of the study. Overall no major differences in trend are seen compared to the primary analysis. If the sponsor's proposed reason for analyzing the first 6 months data were to be correct (that subjects discontinue diclofenac before CSUGIEs occur); this is relevant and important to the safety profile of the drugs under study. However it does not explain the event over time pattern for ibuprofen (table 20.3).*

*Sponsor's table 8.h confirms the fact that for a combined endpoint such as PUB, the majority of events will be symptomatic ulcers without major clinical outcomes such as hospitalization, bleed or mortality. Thus, the combined endpoint is not as informative as separate endpoints for symptomatic ulcers and complicated ulcers. If trends are adequately consistent for both endpoints and well correlated, a combined endpoint is potentially meaningful.*

**Table 8.h. Distributions of CSUGIEs/GDUs by Category: Traditional Definitions - First Six Months**

Event Category	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
<b>UGI Bleeding (Category 1)</b>			
1A: Hematemesis with ulcer/large erosion	-	-	-
1B: Ulcer/large erosion with evidence of bleeding	7	4	7
1C: Melena with ulcer/large erosion	3 *	4	3 †
1D-1: Hemocult-positive stool with ulcer/large erosion and hematocrit/hemoglobin drop	2 *	1	3
1D-2: Hemocult-positive stool with ulcer/large erosion and orthostasis	-	-	-
1D-3: Hemocult-positive stool with ulcer/large erosion and transfusion	-	-	-
1D-4: Hemocult-positive stool with ulcer/large erosion and blood in stomach	-	-	-
<b>UGI Perforation (Category 2)</b>	-	-	-
<b>Gastric Outlet Obstruction (Category 3)</b>	1	-	-
<b>Symptomatic Ulcers</b>			
Gastroduodenal‡	19	11	18
Gastric	13	8	17
Duodenal	7	5	1
<b>Total</b>	<b>32</b>	<b>20</b>	<b>31</b>
<b>Total Uncensored</b>	<b>30</b>	<b>20</b>	<b>29</b>

Derived from Tables T17.1, T19, and T23.1 through T23.3 and Appendix 2.6.1. Entries are numbers of patients. See Section 6. 4. 3. 1. for full definitions.

\* One of these events censored from primary analysis. † Two of these events censored.

‡ Any patient with both gastric and duodenal ulcers is counted once in the "Gastroduodenal" row.

**Table 8.i. Summary of CSUGIE/GDU Incidence: Traditional Definitions - First Six Months**

	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID	Log-Rank P Values for Celecoxib Vs:		
				Diclo	Ibu	Both
<b>All Patients</b>						
	n=3987	n=1996	n=1985			
No. of CSUGIEs/GDUs						
Uncensored	30	20	29			
Censored	2	0	2			
Total	32	20	31			
Week 26 crude rate†	0.75%	1.00%	1.46%	0.308	0.005	0.023
No. per 100 pt-yrs†	2.08	2.82	4.31			
<b>Patients not Taking Aspirin</b>						
	n=3154	n=1567	n=1602			
No. of CSUGIEs/GDUs						
Uncensored	16	9	23			
Censored	1	0	1			
Total	17	9	24			
Week 26 crude rate†	0.51%	0.57%	1.44%	0.760	<0.001	0.017
No. per 100 pt-yrs†	1.40	1.61	4.25			

Derived from Tables T17.1 through T18.3.

† Censoring rule applied.

*An alternate hypothesis to that suggested by the sponsor for why C and diclofenac results are similar in all analyses is that impending CSUGIEs in subjects on C give less warning and do not result in timely discontinuation of the drug. This interpretation is equally plausible and is more worrisome for a clinical standpoint. Both the sponsor's and this reviewer's proposed interpretations of the time to event results are conjectural. As such, the sponsor's presentations of 6-month data as well as the imputed results not presented in this review are not statistically valid or supportable.*

***Based on the lack of adequate rationale, these post-hoc analyses will not be further discussed or presented in this review.***

**Overall conclusions of analysis of GI endpoints**

- 1.** *The sponsor has failed to demonstrate a statistically significant lower rate of CSUGIEs (traditional or alternate) compared to NSAIDs as a group or either individual comparator. In the “all subjects analysis” there is no meaningful trend among the three comparator groups.*
- 2.** *In subjects not taking aspirin, there is a strong trend in favor of C compared to ibuprofen for a lower rate of CSUGIEs. The statistical significance of the p value of .037 would be lost were it to be subjected to correction for multiple comparisons.*
- 3.** *A secondary endpoint of CSUGIE/GDU (PUB) reflects the same trends as the primary analysis of CSUGIEs. This endpoint analysis controls serves as a control or sensitivity analysis for any potential bias that may have been introduced by a higher withdrawal rate of subjects in the diclofenac group due to UGI symptoms compared to the other two groups. The differences seen between “all subjects” and “nonaspirin users” also reflect the same trends seen in the primary endpoint, CSUGIEs.*
- 4.** *In subjects requiring low dose aspirin, there was no superiority for C compared to either traditional NSAID at endpoints, CSUGIEs and CSUGIE/GDU (PUBs). The trends seen in event rates in relation to C for the two traditional NSAID comparators were reversed (compared with the nonaspirin population). There was a trend favoring the safety of ibuprofen over C and diclofenac (when used along with aspirin) for both endpoints. There may be an interaction between aspirin and NSAIDs that is drug rather than class specific.*
- 5.** *The sponsor’s presentation of results of post hoc analyses at 6 months:*
  - a.** *does not add to the primary analysis of entire study results*
  - b.** *censors important data on longer duration of exposure that reflects use in practice*
  - c.** *does not correct for a putative bias introduced by informative censoring of subjects who withdrew due to UGI symptoms*
- 6.** *There appears to be a higher risk of late CSUGIEs with C compared to both ibuprofen and diclofenac. Informed censoring based on differential withdrawal rates cannot be invoked to explain the results in the ibuprofen group and therefore cannot be assumed to explain the results in the diclofenac group.*
- 7.** *Imputation of event rates is not supported by the evidence reviewed by this reviewer.*

- a. *The high “GI adverse event” rate noted by the sponsor in the diclofenac subjects that experienced CSUGIEs reflects the clinical presentation of the CSUGIE and cannot be used calculate a correction or imputation of an event rate in subjects who withdraw due to GI symptoms in the absence of a CSUGIE.*
- b. *The results of the analysis of CSUGIE/GDU (PUB) corrects for any putative informative censoring. The results of this analysis support the primary analysis.*
- c. *The ibuprofen and diclofenac groups experienced similar patterns over time in event rates despite the greater similarity between ibuprofen and C in withdrawals due to UGI adverse events.*

### **External sources of relevant data**

*Review of the data from the original NDA submission may inform interpretation of the current trial. The results of the **endoscopic** studies submitted with the original NDA failed to show replicated superiority of C compared to diclofenac. Furthermore the nominal superiority in ulcer rates between the C groups and the diclofenac groups were smaller than with the other two NSAID comparators used in the original NDA endoscopic ulcer studies, (ibuprofen and naproxen). Thus the endoscopic studies are consistent in trend to the current outcome study in identifying less difference between C and diclofenac compared to ibuprofen. The meta-analysis of CSUGIEs presented by the sponsor in the original NDA had only 2 event in each of the databases of C and diclofenac. This database is too small to meaningfully inform this discussion.*

*There is a large body of literature that supports the view that there is variability in GI toxicity within the drug class NSAID.<sup>4-9</sup> This literature reflects results from uncontrolled observational studies, case controlled and epidemiological studies using various endpoints of UGI toxicity including serious bleeding, hospitalization and symptoms. There are many limitations to these studies. These limitations have restricted clinician’s ability to meaningfully differentiate the safety among the various NSAIDs. The tables below are reprinted from the references noted. They are limited due to the inherent limitation of uncontrolled study.*

*Overall, these studies suggest multiple-fold differences in the GI toxicity of traditional NSAIDs. The current study supports variability in traditional NSAID toxicity. The results of the current CLASS study are the best controlled study available comparing the safety of 2 NSAIDs.*

***Possibly the most important result of the current study is the corroboration in a large well controlled outcome study that there exists a range of toxicity among the various traditional NSAIDs. COX-2 agents may fall within the spectrum of COX inhibitors and***

*therefore need to be considered in relation to individual NSAIDs rather than to an entire class.*

***Risk factors:***

*Tables 24.2, and 25.2 confirm the impact of past history of GI events and cardiovascular disease on the incidence of CSUGIEs. There has been some debate in the medical literature as to the impact of H. pylori infection on the incidence of CSUGIE associated with the use of NSAIDs.*

***CSUGIEs:*** *Risk factors that appear to be different between C and the less selective COX NSAIDs include alcohol use, H.pylori infection. It is unclear whether this apparent difference is meaningful given the multiple comparisons being made and the small number of subjects in some cells.*

*Tobacco use appeared protective overall. This is contrary to other literature. The meaning of this finding is unclear.*

***CSUGIEs/GDU:*** *The patterns were somewhat different for this composite endpoint compared to CSUGIEs alone. The meaning of this finding is not clear.*

Advisory Committee Briefing Document  
February 7, 2000

Table T24.2  
Risk Factor Analysis of Clinically Significant UGI Events (GI History)

	Intent-to-Treat (ITT) Cohort			P-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)		
HISTORY OF UPPER GI BLEEDING					
YES	1/ 68 ( 1.5%)	0/ 30 ( 0.0%)	2/ 28 ( 7.1%)	0.207	0.017
NO	16/3919 ( 0.4%)	10/1966 ( 0.5%)	9/1957 ( 0.5%)		
P-VALUE (b)	0.144	0.994	<0.001		
HISTORY OF GASTRODUODENAL ULCER					
YES	2/ 334 ( 0.6%)	4/ 170 ( 2.4%)	1/ 151 ( 0.7%)	0.189	0.030
NO	15/3653 ( 0.4%)	6/1826 ( 0.3%)	10/1834 ( 0.5%)		
P-VALUE (b)	0.509	0.002	0.762		
HISTORY OF UPPER GI BLEEDING OR GASTRODUODENAL ULCER					
YES	2/ 353 ( 0.6%)	4/ 180 ( 2.2%)	2/ 162 ( 1.2%)	0.263	0.012
NO	15/3634 ( 0.4%)	6/1816 ( 0.3%)	9/1823 ( 0.5%)		
P-VALUE (b)	0.554	0.003	0.183		
HISTORY OF GI-RELATED NSAID INTOLERANCE					
YES	3/ 347 ( 0.9%)	2/ 202 ( 1.0%)	2/ 165 ( 1.2%)	0.993	0.055
NO	14/3640 ( 0.4%)	8/1794 ( 0.4%)	9/1820 ( 0.5%)		
P-VALUE (b)	0.183	0.272	0.222		
HISTORY OF CARDIOVASCULAR DISEASE					
YES	14/1602 ( 0.9%)	7/ 805 ( 0.9%)	4/ 794 ( 0.5%)	0.036	<0.001
NO	3/2384 ( 0.1%)	3/1190 ( 0.3%)	7/1190 ( 0.6%)		
P-VALUE (b)	0.002	0.064	0.793		
FLEXSURE FOR H. PYLORI					
POSITIVE	5/1536 ( 0.3%)	5/ 752 ( 0.7%)	7/ 769 ( 0.9%)	0.170	0.385
NEGATIVE	12/2448 ( 0.5%)	5/1243 ( 0.4%)	4/1213 ( 0.3%)		
P-VALUE (b)	0.460	0.417	0.092		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.

(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

# Advisory Committee Briefing Document

## February 7, 2000

Table T25.2  
Risk Factor Analysis of Clinically Significant UGI Events (Medication, Alcohol, and Tobacco Use)

	Intent-to-Treat (ITT) Cohort			----- P-Value (a) -----	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)		
CORTICOSTEROID USE					
ANY	3/1219 ( 0.2%)	2/ 568 ( 0.4%)	2/ 607 ( 0.3%)	0.954	0.045
NONE	14/2768 ( 0.5%)	8/1428 ( 0.6%)	9/1378 ( 0.7%)		
P-VALUE (b)	0.171	0.503	0.276		
ASPIRIN USE					
ANY	9/ 882 ( 1.0%)	6/ 445 ( 1.3%)	1/ 412 ( 0.2%)	0.020	0.006
NONE	8/3105 ( 0.3%)	4/1551 ( 0.3%)	10/1573 ( 0.6%)		
P-VALUE (b)	0.005	0.010	0.335		
ALCOHOL USE					
ANY	4/1232 ( 0.3%)	5/ 812 ( 0.6%)	4/ 386 ( 1.0%)	0.326	0.605
NONE	13/2753 ( 0.5%)	5/1184 ( 0.4%)	7/1599 ( 0.4%)		
P-VALUE (b)	0.506	0.574	0.166		
TOBACCO USE					
ANY	0/ 628 ( 0.0%)	2/ 311 ( 0.6%)	0/ 284 ( 0.0%)	0.057	0.059
NONE	17/3356 ( 0.5%)	8/1685 ( 0.5%)	11/1701 ( 0.6%)		
P-VALUE (b)	0.993	0.657	0.992		
ANTICOAGULANT USE					
ANY	0/ 42 ( 0.0%)	0/ 24 ( 0.0%)	0/ 20 ( 0.0%)	1.000	0.339
NONE	17/3945 ( 0.4%)	10/1972 ( 0.5%)	11/1965 ( 0.6%)		
P-VALUE (b)	0.993	0.994	0.994		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.

(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Advisory Committee Briefing Document  
February 7, 2000

Table T25.4  
Risk Factor Analysis of Clinically Significant UGI Events or GD Ulcer (Medication, Alcohol, and Tobacco Use)

	Intent-to-Treat (ITT) Cohort			P-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)		
<b>CORTICOSTEROID USE</b>					
ANY	10/1219 ( 0.8%)	6/ 568 ( 1.1%)	12/ 607 ( 2.0%)	0.707	0.123
NONE	33/2768 ( 1.2%)	20/1428 ( 1.4%)	24/1378 ( 1.7%)		
P-VALUE (b)	0.150	0.397	0.778		
<b>ASPIRIN USE</b>					
ANY	22/ 882 ( 2.5%)	16/ 445 ( 3.6%)	8/ 412 ( 1.9%)	0.004	<0.001
NONE	21/3105 ( 0.7%)	10/1551 ( 0.6%)	28/1573 ( 1.8%)		
P-VALUE (b)	<0.001	<0.001	0.960		
<b>ALCOHOL USE</b>					
ANY	10/1232 ( 0.8%)	15/ 812 ( 1.8%)	5/ 386 ( 1.3%)	0.112	0.924
NONE	33/2753 ( 1.2%)	11/1184 ( 0.9%)	31/1599 ( 1.9%)		
P-VALUE (b)	0.351	0.099	0.463		
<b>TOBACCO USE</b>					
ANY	2/ 628 ( 0.3%)	5/ 311 ( 1.6%)	2/ 284 ( 0.7%)	0.106	0.054
NONE	41/3356 ( 1.2%)	21/1685 ( 1.2%)	34/1701 ( 2.0%)		
P-VALUE (b)	0.074	0.508	0.146		
<b>ANTICOAGULANT USE</b>					
ANY	1/ 42 ( 2.4%)	0/ 24 ( 0.0%)	0/ 20 ( 0.0%)	0.382	0.821
NONE	42/3945 ( 1.1%)	26/1972 ( 1.3%)	36/1965 ( 1.8%)		
P-VALUE (b)	0.453	0.994	0.994		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.  
(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Tables 8.l and 8.m reinforce the higher risk of CSUGIEs in the elderly and those with a history of UGI complications of prior NSAID therapy and those on aspirin therapy. C did not appear to offer a unique advantage in high risk patients.

**Table 8.l. Univariate Analysis of Risk Factors for CSUGIEs and CSUGIEs/GDUs**

Factor	Relative Risk			
	CSUGIEs		CSUGIEs/GDUs	
	Celecoxib 400 mg BID	NSAIDs	Celecoxib 400 mg BID	NSAIDs
Age ≥75 years	5.0 (p<0.001)	5.8 (p<0.001)	3.5 (p<0.001)	3.7 (p<0.001)
Patient's Global Assessment (Baseline)	2.5 (p=0.037)	2.4 (p=0.045)	1.4 (p=0.202)	1.4 (p=0.144)
History of UGI bleeding	3.6 (p=0.144)	7.1 (p=0.006)	4.3 (p=0.006)	3.4 (p=0.019)
History of GD ulcer	1.5 (p=0.509)	3.6 (p=0.009)	2.9 (p=0.002)	2.7 (p<0.001)
History of NSAID intolerance	2.2 (p=0.183)	2.3 (p=0.105)	3.2 (p=0.001)	1.9 (p=0.037)
History of CV disease	6.9 (p=0.002)	1.6 (p=0.240)	2.5 (p=0.002)	1.6 (p=0.048)
Positive <i>H. pylori</i> serology	0.7 (p=0.460)	2.2 (p=0.072)	1.1 (p=0.423)	2.0 (p=0.005)
Aspirin use	4.0 (p=0.005)	1.8 (p=0.211)	3.7 (p<0.001)	2.3 (p=0.002)

Derived from Tables T23.1, T23.3, T24.1, T24.3, T25.1, and T25.3.

**Table 8.m. Multivariate Analysis of Risk Factors for CSUGIEs/GDUs**

Treatment Group	Factor	Odds Ratio (p Value)
Celecoxib	Aspirin use	2.9 (p<0.001)
	History of GD ulcer	2.5 (p=0.018)
	Age ≥75 years	2.4 (p=0.012)
NSAIDs	Age ≥75 years	3.3 (p<0.001)
	History of GD ulcer	2.6 (p=0.004)
	Aspirin use	2.1 (p=0.006)

**Table 8.q. Distributions of CSUGIEs and CSUGIEs/GDUs by Number of Risk Factors and Treatment Group**

Number of Risk Factors	Number of Patients	No. (%) with CSUGIE	No. (%) with CSUGIE/GDU	No. (%) Withdrawing
Celecoxib 400 mg BID				
0	2029	1 (<0.1)	7 (0.3)	1045 (52)
1	1497	8 (0.5)	20 (1.3)	856 (57)
≥2	461	8 (1.7)	16 (3.5)	307 (67)
Diclofenac 75 mg BID				
0	1019	0 (0.0)	2 (0.2)	485 (48)
1	738	4 (0.5)	13 (1.8)	416 (56)
≥2	239	6 (2.5)	11 (4.6)	156 (65)
Ibuprofen 800 mg TID				
0	1025	5 (0.5)	16 (1.6)	654 (64)
1	758	2 (0.3)	10 (1.3)	488 (64)
≥2	202	4 (2.0)	10 (5.0)	152 (75)

Derived from Appendix 1.9.

**Risk associated with disease: Osteoarthritis /Rheumatoid Arthritis**

Table T23.2  
Risk Factor Analysis of Clinically Significant UGI Events (Demographics)

	Intent-to-Treat (ITT) Cohort			Treatment by Factor Interaction	P-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)			
AGE (years)						
<75	10/3500 ( 0.3%)	5/1760 ( 0.3%)	7/1768 ( 0.4%)			
>=75	7/ 487 ( 1.4%)	5/ 236 ( 2.1%)	4/ 217 ( 1.8%)	0.837		<0.001
P-VALUE (b)	<0.001	<0.001	0.007			
GENDER						
MALE	6/1255 ( 0.5%)	6/ 650 ( 0.9%)	4/ 580 ( 0.7%)			
FEMALE	11/2732 ( 0.4%)	4/1346 ( 0.3%)	7/1405 ( 0.5%)	0.476		0.170
P-VALUE (b)	0.765	0.083	0.625			
DISEASE TYPE						
OA	14/2698 ( 0.5%)	8/1453 ( 0.6%)	8/1434 ( 0.6%)			
RA	3/1089 ( 0.3%)	2/ 543 ( 0.4%)	3/ 551 ( 0.5%)	0.855		0.312
P-VALUE (b)	0.341	0.597	0.928			
DURATION (OA)						
< 5 YEARS	3/ 965 ( 0.3%)	3/ 484 ( 0.6%)	6/ 497 ( 1.2%)			
>= 5 YEARS	11/1910 ( 0.6%)	5/ 963 ( 0.5%)	2/ 927 ( 0.2%)	0.052		0.519
P-VALUE (b)	0.327	0.824	0.038			
DURATION (RA)						
< 5 YEARS	2/ 333 ( 0.6%)	0/ 191 ( 0.0%)	0/ 168 ( 0.0%)			
>= 5 YEARS	1/ 738 ( 0.1%)	2/ 345 ( 0.6%)	3/ 374 ( 0.8%)	0.065		0.640
P-VALUE (b)	0.229	0.992	0.994			
PATIENT'S GLOBAL ASSESSMENT AT BASELINE						
POOR OR VERY POOR	6/ 713 ( 0.8%)	5/ 362 ( 1.4%)	2/ 335 ( 0.6%)			
OTHER	11/3274 ( 0.3%)	5/1634 ( 0.3%)	9/1650 ( 0.5%)	0.352		0.007
P-VALUE (b)	0.037	0.012	0.819			

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.  
(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Tables 23.2, 23.3, and 23.4 suggest that there is no consistently higher risk for UGI toxicity in patients with RA compared to those with OA. This is in conflict with published less well-controlled studies. Co-morbid conditions more common in RA patients but not included in the current study may account for the conflicting results.

Advisory Committee Briefing Document  
February 7, 2000

Table T23.3  
Risk Factor Analysis of Clinically Significant UGI Events or GD Ulcer (Demographics) - NSAIDs Pooled

	Intent-to-Treat (ITT) Cohort		----- P-Value (a) -----	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	NSAIDs (N = 3981)		
AGE (years)				
<75	29/3500 ( 0.8%)	42/3528 ( 1.2%)	0.739	<0.001
≥75	14/ 487 ( 2.9%)	20/ 453 ( 4.4%)		
P-VALUE(b)	<0.001	<0.001		
GENDER				
MALE	15/1255 ( 1.2%)	21/1230 ( 1.7%)	0.962	0.546
FEMALE	28/2732 ( 1.0%)	41/2751 ( 1.5%)		
P-VALUE(b)	0.666	0.665		
DISEASE TYPE				
OA	31/2898 ( 1.1%)	44/2887 ( 1.5%)	0.955	0.987
RA	12/1089 ( 1.1%)	18/1094 ( 1.6%)		
P-VALUE(b)	0.976	0.955		
DURATION (OA)				
< 5 YEARS	12/ 965 ( 1.2%)	17/ 981 ( 1.7%)	0.991	0.402
≥ 5 YEARS	19/1910 ( 1.0%)	26/1890 ( 1.4%)		
P-VALUE(b)	0.583	0.518		
DURATION (RA)				
< 5 YEARS	4/ 333 ( 1.2%)	3/ 359 ( 0.8%)	0.180	0.280
≥ 5 YEARS	7/ 758 ( 0.9%)	15/ 719 ( 2.1%)		
P-VALUE(b)	0.754	0.121		
PATIENT'S GLOBAL ASSESSMENT AT BASELINE				
POOR OR VERY POOR	10/ 713 ( 1.4%)	14/ 697 ( 2.0%)	0.997	0.064
OTHER	33/3274 ( 1.0%)	48/3284 ( 1.5%)		
P-VALUE(b)	0.202	0.144		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.  
(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

Advisory Committee Briefing Document  
February 7, 2000

Table T23.4  
Risk Factor Analysis of Clinically Significant UGI Events or GD Ulcer (Demographics)

	Intent-to-Treat (ITT) Cohort			D-Value (a)	Factor Effect
	Celecoxib 400 mg BID (N = 3987)	Diclofenac 75 mg BID (N = 1996)	Ibuprofen 800 mg TID (N = 1985)		
AGE (years)					
<75	29/3500 ( 0.8%)	16/1760 ( 0.9%)	26/1768 ( 1.5%)	0.759	<0.001
>=75	14/ 487 ( 2.9%)	10/ 236 ( 4.2%)	10/ 217 ( 4.6%)		
P-VALUE (b)	<0.001	<0.001	<0.001		
GENDER					
MALE	15/1255 ( 1.2%)	11/ 650 ( 1.7%)	10/ 580 ( 1.7%)	0.674	0.525
FEMALE	28/2732 ( 1.0%)	15/1346 ( 1.1%)	26/1405 ( 1.9%)		
P-VALUE (b)	0.666	0.324	0.812		
DISEASE TYPE					
OA	31/2898 ( 1.1%)	21/1453 ( 1.4%)	23/1434 ( 1.6%)	0.410	0.996
RA	12/1089 ( 1.1%)	5/ 543 ( 0.9%)	13/ 551 ( 2.4%)		
P-VALUE (b)	0.976	0.323	0.374		
DURATION (OA)					
< 5 YEARS	12/ 965 ( 1.2%)	6/ 484 ( 1.2%)	11/ 497 ( 2.2%)	0.413	0.403
>= 5 YEARS	19/1910 ( 1.0%)	15/ 963 ( 1.6%)	11/ 927 ( 1.2%)		
P-VALUE (b)	0.583	0.608	0.169		
DURATION (RA)					
< 5 YEARS	4/ 333 ( 1.2%)	0/ 191 ( 0.0%)	3/ 168 ( 1.8%)	0.119	0.315
>= 5 YEARS	7/ 738 ( 0.9%)	5/ 345 ( 1.4%)	10/ 374 ( 2.7%)		
P-VALUE (b)	0.754	0.992	0.485		
PATIENT'S GLOBAL ASSESSMENT AT BASELINE					
POOR OR VERY POOR	10/ 713 ( 1.4%)	8/ 362 ( 2.2%)	6/ 335 ( 1.8%)	0.569	0.061
OTHER	33/3274 ( 1.0%)	18/1634 ( 1.1%)	30/1650 ( 1.8%)		
P-VALUE (b)	0.202	0.062	0.763		

(a) Based on survival analysis on the time to UGI events with a COX proportional hazards model.  
(b) Within group survival analysis on the time to UGI events with a COX proportional hazards model.

**Overall safety profile**

*Review of the GI adverse events, adverse events, adverse events causing withdrawal and serious adverse events are displayed in tables 10.d, e, f, g, and 10.o. There are no substantial differences between C and the NSAIDs as a group. The differences seen in GI adverse events, as well as other adverse events are drug specific rather than COX-selectively specific in incidence. Causality is not implied in the non-GI adverse events. A similar pattern is seen in overall mortality as shown in table 10.e and 10.f.*

***The overall rate of serious outcomes (of which UGI events is but a fraction) is comparable among groups. While differences exist among the individual drugs, these tables support a conclusion that there is similarity among all three groups in overall morbidity and mortality. This may be the most important finding of the CLASS study.***

Advisory Committee Briefing Document  
February 7, 2000

**Table 10.o. Summary of GI Adverse Events by Aspirin Use: Entire Study Period**

Adverse Event	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID
<b>Patients not Taking Aspirin</b>			
No. of patients	3105	1551	1573
<b>Any GI event</b>	<b>43.3</b>	<b>53.8 *</b>	<b>44.5</b>
Dyspepsia	15.6	19.5 *	15.6
Abdominal pain	10.9	17.3 *	10.7
Diarrhea	10.5	13.9 *	7.2 *
Nausea	8.0	11.6 *	8.5
Flatulence	7.1	10.8 *	7.5
Tooth disorder	2.3	4.1 *	3.9 *
Vomiting	2.4	3.4	3.0
Constipation	1.9	6.5 *	5.9 *
<b>Any GI event causing withdrawal</b>	<b>11.5</b>	<b>15.4 *</b>	<b>13.2</b>
<b>Patients Taking Aspirin</b>			
No. of patients	882	445	412
<b>Any GI event</b>	<b>54.0</b>	<b>59.1</b>	<b>52.7</b>
Dyspepsia	19.7	19.8	19.9
Abdominal pain	14.5	22.7 *	13.6
Diarrhea	12.1	18.6 *	8.3 *
Nausea	9.0	13.9 *	10.7
Flatulence	7.9	13.5 *	6.1
Tooth disorder	5.0	4.7	6.1
Vomiting	3.1	3.8	1.5
Constipation	3.3	7.9 *	9.0 *
Gastroenteritis	2.8	3.1	1.7
Gastroesophageal reflux	3.5	2.2	2.2
Hemoccult positivity	2.7	3.1	3.9
<b>Any GI event causing withdrawal</b>	<b>14.9</b>	<b>20.7 *</b>	<b>14.1</b>

Derived from Tables T41.2, T41.3, T42.2, and T42.3. All numbers are percentages of patients. Includes any GI adverse event with incidence  $\geq 3\%$  in any treatment group.

\*  $p < 0.05$  vs celecoxib 400 mg BID.

**Table 10.d. Adverse Events Causing Withdrawal with Incidence  $\geq 1\%$  in Any Treatment Group: Entire Study Period**

Adverse Event	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Any event	22.4	26.5 *	23.0
Abdominal pain	4.3	6.5 *	4.9
Dyspepsia	3.8	4.4	3.9
Rash	2.1	0.7 *	1.3 *
Nausea	1.7	2.8 *	1.8
Diarrhea	1.4	2.7 *	0.8 *
Flatulence	1.2	1.8	1.4
Gastric ulcer	0.3	0.7	1.0 *
SGOT increased	0.1	2.1 *	0.1
SGPT increased	0.1	2.3 *	0.1
Hepatic function abnormal	<0.1	1.1 *	<0.1

Derived from Table T42.1. All numbers are percentages of patients unless otherwise specified.

\*  $p < 0.05$  vs celecoxib 400 mg BID.

Advisory Committee Briefing Document  
February 7, 2000

**Table 10.g. Summary of Serious Adverse Events: Entire Study Period**

Adverse Event	Celecoxib 400 mg BID (n=3987) 2320.4 pt-yrs	Diclofenac 75 mg BID (n=1996) 1080.5 pt-yrs	Ibuprofen 800 mg TID (n=1985) 1122.5 pt-yrs
Any serious event	270 (11.6)	111 (10.3)	119 (10.6)
Abdominal pain	6 (0.3)	6 (0.6)	2 (0.2)
Accidental fracture	10 (0.4)	4 (0.4)	9 (0.8)
Accidental injury	3 (0.1)	4 (0.4)	7 (0.6)
Angina pectoris	4 (0.2)	5 (0.5)	6 (0.5)
Atrial fibrillation	9 (0.4)	2 (0.2)	3 (0.3)
Back pain	15 (0.6)	3 (0.3)	9 (0.8)
Cardiac failure	9 (0.4)	2 (0.2)	9 (0.8)
Cellulitis	8 (0.3)	1 (<0.1)	1 (<0.1)
Cerebrovascular disorder	4 (0.2)	6 (0.6)	6 (0.5)
Chest pain	11 (0.5)	5 (0.5)	7 (0.6)
Coronary artery disorder	19 (0.8)	5 (0.5)	5 (0.4)
Deep thrombophlebitis	7 (0.3)	5 (0.5)	1 (<0.1)
GI hemorrhage	7 (0.3)	2 (0.2)	1 (<0.1)
Myocardial infarction	19 (0.8)	4 (0.4)	9 (0.8)
Pneumonia	14 (0.6)	5 (0.5)	5 (0.4)
Syncope	5 (0.2)	4 (0.4)	3 (0.3)
Unstable angina	8 (0.3)	4 (0.4)	0

Derived from Table T43. All numbers represent number of patients (number per 100 patient-years). Table includes any event experienced by a total of at least 10 patients across the three treatment groups.

**Table 10.e. Summary of Deaths Occurring During Treatment or Within 28 Days After Discontinuation of Treatment: Entire Study Period**

Adverse Event*	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Myocardial infarction	3	-	1
Cardiac arrest	1	4	1
Accidental injury	1	-	-
Circulatory failure/Myocardial infarction	-	-	1
Sepsis	1	-	-
Carcinoma	1	-	-
Coronary artery disorder	-	1	-
Arrhythmia/Myocardial infarction	1	-	-
<b>Total (No. per 100 pt-yr)</b>	<b>8 (0.34)</b>	<b>5 (0.46)</b>	<b>3 (0.27)</b>

Derived from Appendix 2.9.1 and Appendix 3.7. Table includes only deaths that occurred during treatment or within 28 days after last dose.

\* For cases in which no adverse event preferred term is available, event is classified by cause of death listed on end-of-study CRF.

Advisory Committee Briefing Document  
February 7, 2000

**Table 10.f. Summary of Deaths Occurring More Than 28 Days After Discontinuation of Treatment: Entire Study Period**

Adverse Event *	Celecoxib 400 mg BID (n=3987)	Diclofenac 75 mg BID (n=1996)	Ibuprofen 800 mg TID (n=1985)
Myocardial infarction	2	-	1
Cardiac arrest	1	1	-
Pulmonary fibrosis/Pneumonia	-	-	1
Carcinoma	1	-	-
Coronary artery disorder	1	-	1
Cardiac arrest/cardiac tamponade	1	-	-
Aneurysm/Subarachnoid hemorrhage	-	1	-
Cerebrovascular disorder	1	-	-
Accidental injury	-	-	1
Pneumonia	1	-	-
Cardiac failure	-	-	1
Pulmonary fibrosis	1	-	-
Pulmonary carcinoma	-	2	-
Sepsis	1	-	-
Cardiopulmonary arrest/hypertension	1	-	-
<b>Total (No. per 100 pt-yr)</b>	<b>11 (0.47)</b>	<b>4 (0.37)</b>	<b>5 (0.45)</b>

Derived from Appendix 2.9.1 and Appendix 3.7. Table includes only deaths that occurred more than 28 days after last dose.

\* For cases in which no adverse event preferred term is available, event is classified by cause of death listed on end-of-study CRF.

**Laboratory values**

*The mean changes in Hgb and Hct seen in sponsor table 10.l are notable. The endpoint is suggestive of a clinically relevant event (drop of 2 units in Hgb or 10% in Hct). The lack of any trend in parameters of renal function or fluid status displayed in table 10.q suggest that the lower rates of significant drops in hematological parameters may well be due to slow GI blood loss. This finding may be as meaningful as the composite endpoint of CSUGIE/GDU since large drops in Hgb and Hct. predispose to clinically relevant outcomes such as myocardial infarction, arrhythmia, congestive heart failure and syncope as well as others. In this trial, frequent monitoring likely prevented the occurrence of these events. In less well-structured follow-up such differences in a large population may result in clinically relevant differences in outcomes.*

Advisory Committee Briefing Document  
February 7, 2000

**Table 10.h. Mean Changes from Baseline to Final Visit in Laboratory Values**

Laboratory Test	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID
Hemoglobin, g/dL	-0.06 (0.013)	-0.26 (0.020) *	-0.37 (0.019) *
Hematocrit	-0.001 (0.0004)	-0.007 (0.0006) *	-0.012 (0.0007) *
Platelet count, x10 <sup>9</sup> /L	-2.3 (0.70)	10.0 (1.11) *	7.9 (0.94) *
WBC, x10 <sup>9</sup> /L	-0.09 (0.029)	0.06 (0.038) *	0.01 (0.041) *
Total bilirubin, µmol/L	0.0 (0.05)	0.1 (0.06)	-1.0 (0.07) *
Alkaline phosphatase, U/L	0.9 (0.23)	1.6 (0.38) *	-0.5 (0.31) *
AST, U/L	0.3 (0.12)	5.0 (0.57) *	0.9 (0.16)
ALT, U/L	-0.2 (0.18)	11.6 (1.10) *	1.3 (0.24)
Creatine kinase, U/L	-2.0 (1.17)	1.3 (2.18)	-0.1 (1.97)
Creatinine, µmol/L	0.8 (0.22)	2.4 (0.33) *	1.5 (0.33)
BUN, mmol/L	0.66 (0.027)	0.58 (0.041)	0.52 (0.039) *
Sodium, mmol/L	-0.1 (0.05)	-0.4 (0.07) *	0.0 (0.07)
Potassium, mmol/L	0.05 (0.007)	0.03 (0.010)	-0.03 (0.010) *
Chloride, mmol/L	0.7 (0.05)	0.4 (0.07) *	0.7 (0.07)
Bicarbonate, mmol/L	0.2 (0.04)	0.3 (0.06)	0.1 (0.06) *
Inorganic phosphorus, mmol/L	0.009 (0.0030)	-0.012 (0.0042) *	-0.003 (0.0046)

Derived from Table T44.1. All numbers are mean (SE) changes from Baseline.  
\* p<0.05 vs. celecoxib 400 mg BID.

**Table 10.I. Summary of Hemoglobin/Hematocrit Contingency Tables: Entire Study Period**

Patients with hemoglobin decrease >2 g/dL and/or hematocrit decrease ≥0.10	Celecoxib 400 mg BID	Diclofenac 75 mg BID	Ibuprofen 800 mg TID
All patients	87/3701 (2.4)	82/1849 (4.4)	102/1802 (5.7)
Excluding CSUGIEs	83/3682 (2.3)	81/1840 (4.4)	95/1792 (5.3)
Excluding CSUGIEs/ulcers	82/3659 (2.2)	78/1824 (4.3)	93/1768 (5.3)
Excluding all adjudicated potential CSUGIEs	73/3545 (2.1)	68/1753 (3.9)	81/1693 (4.8)
Excluding all reported potential CSUGIEs	41/3068 (1.3)	41/1490 (2.8)	42/1364 (3.1)
OA patients	63/2675 (2.4)	48/1340 (3.6)	74/1299 (5.7)
RA patients	24/1026 (2.3)	34/509 (6.7)	28/503 (5.6)
Patients not taking aspirin	53/2864 (1.9)	53/1428 (3.7)	73/1414 (5.2)
Patients taking aspirin	34/837 (4.1)	29/421 (6.9)	29/388 (7.5)

Derived from Tables T46.1 through T46.9. Data are expressed as No./total and percentage of patients who meet the criterion in Column 1.

**Other potential safety concerns**

***Colitis***

*In the original GI review of C (page 47 of Division of Gastrointestinal and Coagulation Drug Products Medical officers Consult Review) concern was raised over the potential for adverse events in the lower GI tract. In the current submission the sponsor noted 1 case of colitis in the C group compared to 1 in the ibuprofen group and three in the diclofenac group. The etiology of colitis is unknown. The lack of a trend towards a higher rate of colitis in the C group is reassuring that this product and highly selective COX-2 inhibition in general are not substantially toxic to the lower GI tract. The impact of a COX-2 selective agent on healing of pre-existing colitis or inflammatory bowel disease is not addressed in the current database.*

***Esophagitis***

*C did not appear to have a meaningfully lower rate of UGI symptoms such as pain and dyspepsia, nausea and vomiting and heartburn compared to the NSAID comparators in the original NDA. This was somewhat surprising in view of the large difference in GDUs. Although it had been clear even before this NDA that UGI symptoms are not highly correlated with endoscopic ulcers, the relative lack of impact on UGI symptoms was impressive. In the current NDA, results on all subjects who underwent endoscopy were reported by organ. The tabulated results appear in reviewer table 2 below. It is possible that the UGI symptoms in the C group as well as in the NSAID comparator group are related to GERD. However, in general a significant number of subjects without symptoms will also have esophageal abnormalities on endoscopic examination. Likewise, the percentage of subjects with endoscopic abnormalities below cannot explain the bulk of UGI symptoms reported in this study. The results do strongly suggest that associated esophageal mucosal abnormalities are similar in the C group compared to the traditional NSAID groups in this study. Attribution cannot be ascribed to the drugs in the table below.*

***Reviewer Table 2***

<i>DRUG</i>	<i>Celebrex 137</i>	<i>ibuprofen</i>	<i>diclofenac</i>
<i>Erosions*</i>	<i>21/137 (15%)</i>	<i>21/105 (20%)</i>	<i>10/89 (11%)</i>
<i>Ulcers*</i>	<i>8/137 (6%)</i>	<i>2/105 (2%)</i>	<i>6/89 (7%)</i>
<i>Ulcers/erosions*</i>	<i>29/137 (21%)</i>	<i>23/105 (22%)</i>	<i>16/89 (18%)</i>
<i>Erosions**</i>	<i>0.5%</i>	<i>1.1%</i>	<i>0.5%</i>
<i>Ulcers**</i>	<i>0.2%</i>	<i>0.1%</i>	<i>0.3%</i>
<i>Ulcers/erosions**</i>	<i>0.7%</i>	<i>1.2%</i>	<i>0.8%</i>

Advisory Committee Briefing Document

February 7, 2000

*\*represents the number of patients with the given finding on EGD/ total # of subjects undergoing endoscopy*

*\*\* represents the % of subjects with the endoscopic finding/ITT population. Note: endoscopies performed on a small nonrandom subset of the ITT*

### Overall Conclusions

Note:

*All comparisons noted reflect comparisons between approved and commonly used dosages of ibuprofen and diclofenac and twice the RA dose for C. However, in the original NDA database, there did not appear to be a meaningful difference in GI tolerance or GDU incidence in subjects on 200 mg-800 mg/day. Furthermore C is currently approved for use at 800mg/day for FAP.*

1. *The sponsor has failed to demonstrate a statistically significant lower rate of CSUGIEs (traditional or alternate) compared to NSAIDs as a group or either individual comparator. In the “all subjects analysis” there is no meaningful trend among the three comparator groups.*
2. *In subjects not taking aspirin, there is a strong trend in favor of C compared to ibuprofen for a lower rate of CSUGIEs.*
3. *A secondary endpoint of CSUGIE/GDU (PUB) reflects the same trends as the primary analysis of CSUGIEs. This analysis controls much of any potential bias that may have been introduced by a higher withdrawal rate of subjects in the diclofenac group due to UGI symptoms compared to the other two groups. The differences seen between “all subjects” and “nonaspirin users” also reflect the same trends seen in the primary endpoint, CSUGIEs.*
4. *In aspirin users:*
  - a. *In subjects requiring low dose aspirin, there was no benefit to the use of C compared to either traditional NSAID at endpoints, CSUGIEs and CSUGIE/GDU (PUBs). The trends seen in event rates in relation to C for the two traditional NSAID comparators were reversed (compared with the nonaspirin population). There was a trend favoring the safety of ibuprofen over C and diclofenac (when used along with aspirin) for both endpoints. There may be an interaction between aspirin and NSAIDs that is drug rather than class specific.*
  - b. *The potential for enhanced UGI toxicity with combined nonselective and selective COX-2 inhibition should be further explored in a prospective manner.*
5. *The sponsor’s presentation of results of post hoc analyses at 6 months:*
  - a. *does not add to the primary analysis of entire study results*
  - b. *censors important data on longer duration of exposure that reflects use in practice*
  - c. *does not control bias that may be introduced by informative censoring of subjects who withdrew due to UGI symptoms*

- 6. *There appears to be a higher risk of late CSUGIEs with C compared to both ibuprofen and diclofenac. Informed censoring based on differential withdrawal rates cannot be invoked to explain the results in the ibuprofen group and therefore cannot be assumed to explain the results in the diclofenac group.***
  
- 7. *Imputation of event rates is not justified.***
  - a. *The high “GI adverse event” rate noted by the sponsor in the diclofenac subjects that experienced CSUGIEs reflects the clinical presentation of the CSUGIE. This rate cannot be used to calculate a correction or imputation of an event rate in subjects who withdraw due to GI symptoms prior to a CSUGIE. A factor in the excess UGI adverse events seen in the diclofenac group may be due to the excess of subjects enrolled into this group with a history of GI-related NSAID intolerance.***
  
  - b. *The results of the analysis of CSUGIE/GDU (PUB) may be anticipated to partially or fully correct for any such informative censoring. The results of this analysis support the primary analysis.***
  
  - c. *The ibuprofen and diclofenac groups experienced similar patterns over time in event rates despite the greater similarity between ibuprofen and C in and withdrawals due to UGI adverse events.***
  
- 8. *In this large well-designed and controlled study, there appears to be no meaningful difference in UGI toxicity associated with NSAIDs between Osteoarthritis and Rheumatoid arthritis. In view of the multiplicity of epidemiological data suggesting otherwise, co-morbid conditions more frequently associated with RA but excluded from the current study, may account for the difference seen in previous studies.***
  
- 9. *There may be a difference between C and both NSAID comparators at meaningful hematologic endpoints of “patients with hemoglobin decreases of >2g/dl and or hematocrit decrease  $\geq$  0.10. This difference may be clinically meaningful. This difference may be associated with occult GI blood loss. However, hemodilution and a primarily hematological process cannot be excluded.***
  
- 10. *Parameters of overall toxicity are similar among the three comparators. Such parameters include; adverse events causing withdrawal, serious adverse events, and deaths occurring during treatment or within 28 days of treatment.***

## *Appendix 1*

*Relevant portions of original protocol*

*(Excerpted from sponsor protocol dated August 18<sup>th</sup> 1998 document number 49-98-22-035)*

Advisory Committee Briefing Document  
February 7, 2000

**2.0 OBJECTIVES**

**2.1 Primary Objective**

The primary objective of this study is to compare the incidence of clinically significant upper gastrointestinal (UGI) adverse events, a composite safety endpoint, comprised of perforation, bleeding or gastric outlet obstruction associated with SC-58635 400 mg BID to that associated with ibuprofen 800 mg TID in patients with OA or RA. The primary analysis of this study will consist of a survival analysis of the UGI adverse events in this study pooled with those of a companion study (N49-98-02-102). The primary comparison will be the incidence of clinically significant UGI adverse events associated with SC-58635 400 mg BID to that associated with NSAID treatment consisting of ibuprofen 800 mg TID, naproxen 500 mg BID or diclofenac 75 mg BID.

**2.2 Secondary Objectives**

The secondary objectives of this study are to:

1. Compare the chronic overall safety and tolerability of SC-58635 versus ibuprofen;
2. Compare the effect of SC-58635 versus ibuprofen on quality of life and patient satisfaction;
3. Compare the effect of SC-58635 versus ibuprofen on indirect costs;
4. Compare the chronic arthritis efficacy of SC-58635 to that of ibuprofen; and
5. Evaluate potential risk factors (e.g., age, gender, H. pylori infection, type of arthritis, cardiovascular disease, concurrent use of oral corticosteroids, and

Company Confidential – G.D. Searle & Co.

# Advisory Committee Briefing Document

## February 7, 2000

history of peptic ulcer and/or gastrointestinal bleeding) for their impact on the effect of treatment on outcome.

### **3.0 MATERIALS AND METHODS**

#### **3.1 Study Design**

This is a double-blind, multicenter, parallel group trial comparing the incidence of clinically significant events associated with SC-58635 400 mg BID to that associated with ibuprofen 800 mg TID in RA and OA patients. Patients, stratified by OA and RA status, will be randomly assigned in an equalized manner to one of the following treatment arms:

- SC-58635 400 mg BID and ibuprofen placebo TID
- SC-58635 placebo BID and ibuprofen 800 mg TID

Follow-up visits will occur 4, 13, 26, 39 and 52 weeks after the first dose of study medication. The trial will continue until the anticipated number of clinically significant UGI adverse events have been observed in both studies; maximum study participation for an individual patient is 52 weeks. All patients will complete a Final Treatment visit which may coincide with the Week 52 visit, or occur at any time up to Week 52 when the trial officially concludes.

#### **3.2 Study Population**

##### 3.2.a Subject Enrollment

Four thousand (4000) patients are expected to be enrolled and randomly assigned to either SC-58635 treatment or ibuprofen treatment. Patients will be randomly assigned in an equalized manner to one of the following treatment arms:

- SC-58635 400 mg BID and ibuprofen placebo TID
- SC-58635 placebo BID and ibuprofen 800 mg TID

##### 3.2.b Criteria for Inclusion

To qualify for enrollment in this study, a patient must satisfy the criteria listed below:

1. The patient must be of legal age of consent or older;

Advisory Committee Briefing Document  
February 7, 2000

2. If the patient is a female and of childbearing potential, she agrees to participate in this study by providing written informed consent, has been using adequate contraception since her last menses and will use adequate contraception during the study, is not lactating, and has had a negative serum pregnancy test within seven days before receiving the first dose of study medication;
3. The patient has a documented clinical diagnosis of OA or RA of at least three months duration;
4. The patient requires chronic NSAID therapy in the Investigator's opinion;
5. The patient is able to participate for the full duration of the study; and
6. The patient has provided written informed consent prior to admission to this study.

3.2.c Criteria for Exclusion

A patient will be excluded from this study if he or she satisfies any one of the criteria listed below:

1. The patient has an active malignancy of any type or history of a malignancy. (Patients who have a history of basal cell carcinoma that has been treated are acceptable. Patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrollment are also acceptable.);
2. The patient has been diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the first dose of study medication;
3. The patient has active GI disease (e.g., inflammatory bowel disease);
4. The patient has a history of gastric or duodenal surgery other than simple oversew of an ulcer or perforation;
5. The patient has significant renal or hepatic dysfunction, or a significant coagulation defect considered by the Investigator to be clinically significant;
6. The patient has abnormal screening laboratory test values  $>1.5$  x the upper limit of normal (ULN) for either AST (SGOT) or ALT (SGPT) or any other laboratory abnormality at Screening considered by the Investigator to be clinically significant;
7. The patient has a positive screening fecal occult blood test result;

Advisory Committee Briefing Document  
February 7, 2000

8. The patient has a known hypersensitivity to COX-2 inhibitors, sulfonamides, or ibuprofen;
9. The patient has received any investigational medication within 30 days prior to the first dose of study medication or is scheduled to receive an investigational drug other than SC-58635 during the course of this study; or
10. The patient has previously been admitted to this study or a prior study with SC-58635.

#### 4.0 STUDY PLAN

##### 4.1 Schedule of Observation and Procedures

	Pretreatment Period -7 to 0 Days		Treatment Period Weeks + Days					Final Visit(b)	Early Term(c)
	Screening	Base- line	4+5	13+5	26+5	39+5	52+ 5(a)		
Informed Consent(d)	X								
Medical History	X								
Physical Exam	X						X	X	X
Clinical Lab Tests(e)	X		X	X	X	X	X	X	X
Pregnancy Test(f)	X			X	X	X	X	X	X
Fecal Occult Blood Testing	X		X		X		X	X	X
D/C Current NSAID & anti-ulcer drugs(g)		X							
Arthritis Assessments		X	X	X	X	X	X	X	X
Signs & Symptoms		X	X	X	X	X	X	X	X
Indirect Cost Assessment		X	X	X	X	X	X	X	X
Patient Satisfaction Questionnaire							X	X	X
QOL Assessments(h)		X			X		X	X	X
Dispense Study Med		X		X	X	X			
Dispense Concurrent Meds Diary Card		X	X	X	X	X			
Retrieve Concurrent Meds Diary Card			X	X	X	X	X	X	X
Return & Count Study Med			X	X	X	X	X	X	X

(a) Use Final Treatment Visit CRFs  
 (b) The Final Treatment Visit coincides with the Week 52 visit or it may occur at any time up to Week 52 when the study has officially concluded  
 (c) Patients terminating early from this study (i.e., before Week 52 or official conclusion) must be contacted monthly for two months following their withdrawal or until the study officially concludes, whichever occurs first  
 (d) Informed consent must be obtained before any study-related procedures are performed  
 (e) Clinical laboratory tests include: **Hematology** (WBC, hemoglobin, hematocrit, platelet count); **Biochemistry** (BUN, creatinine, total bilirubin, alkaline phosphatase, AST (SGOT), ALT (SGPT), creatine kinase (CK), sodium, potassium). At Screening, serum FlexSure HP test for HP status will also be performed.  
 (f) For females of childbearing potential only  
 (g) Current NSAID and anti-ulcer drugs must be discontinued at or before the Baseline Visit  
 (h) SF-36 Health Survey and Health Assessment Questionnaire

#### **4.3 Treatment Period**

The Treatment Period is defined as the 52-week interval during which study medication is taken or until the trial officially concludes, whichever occurs first. The Week 4, Week 13, Week 26, Week 39, Week 52 and the Final Treatment visits occur during this interval.

##### 4.3.b.2 Concurrent Medications

Use of any medication other than the drugs provided for this study will be avoided, if at all possible, during the Treatment period. The following drugs are specifically excluded:

1. NSAIDs, either prescription or nonprescription. (Patients taking  $\leq 325$  mg aspirin per day for reasons other than arthritis, for at least 30 days before the first dose of study medication, may continue the same dose regimen for the duration of the study.);
2. Anti-ulcer drugs (including H<sub>2</sub> antagonists, proton pump inhibitors, sucralfate and misoprostol), either prescription or nonprescription. Short-term use of antacids is permitted (less than seven days consecutively);
3. Antibiotics (i.e., amoxicillin, clarithromycin, azithromycin, tetracycline, metronidazole or bismuth) used alone or combined with omeprazole, lansoprazole, or ranitidine specifically as treatment for H. pylori infection; and
4. Antineoplastics (other than methotrexate  $\leq 25$  mg/wk or azathioprine as treatment for RA).

Acetaminophen ( $\leq 2$  g/day; alone or in combination with propoxyphene hydrochloride or napsalate, hydromorphone hydrochloride, oxycodone hydrochloride or codeine phosphate) may be used as necessary throughout the study. Oral and intrarticular corticosteroids are also allowed.

#### **4.4 Clinically Significant UGI Adverse Events**

Clinically significant UGI adverse events will be classified by consensus of an independent Gastrointestinal Events Committee that will be blinded to the patient's

## Advisory Committee Briefing Document

### February 7, 2000

treatment. Nine categories of signs and symptoms have been established to classify clinically significant UGI adverse events. They are as follows.

#### 4.4.a UGI Perforation

An opening in the wall of the stomach or duodenum requiring surgery, or laparoscopic repair but only if the evidence is unequivocal (free air, peritoneal irritation signs, etc.).

#### 4.4.b UGI Bleeding

UGI bleeding is to be categorized as one of the following seven clinical presentations:

- Hematemesis with a gastric or duodenal ulcer or erosion proven by endoscopy or a UGI barium x-ray;
- A gastric or duodenal ulcer or erosion proven by endoscopy with evidence of active bleeding or stigmata of a recent hemorrhage (visible vessel or attached clot to base of an ulcer);
- Melena with a gastric or duodenal ulcer or erosion proven by endoscopy or barium UGI x-ray;
- Hemocult positive stools with a gastric or duodenal ulcer or erosion proven by endoscopy or barium UGI x-ray and with bleeding as evidenced by a fall in hematocrit of more than 5 percentage points or a reduction of hemoglobin of more than 1.5 g/dL from baseline;
- Hemocult positive stools with a gastric or duodenal ulcer or erosion proven by endoscopy or barium UGI x-ray and with bleeding as evidenced by orthostasis (changes to postural vital signs; increase in pulse rate of  $\geq 20$  beats/min and/or a decrease in systolic blood pressure of  $\geq 20$  mmHg and/or diastolic blood pressure of  $\geq 10$  mmHg);
- Hemocult positive stools with a gastric or duodenal ulcer or erosion proven by endoscopy or barium UGI x-ray and with bleeding as evidenced by a need for blood transfusion of two or more units; or
- Hemocult positive stools with a gastric or duodenal ulcer or erosion proven by endoscopy or barium UGI x-ray and with bleeding as evidenced by blood in the stomach as determined by endoscopy or nasogastric aspiration.

## Advisory Committee Briefing Document February 7, 2000

### 4.4.c Gastric Outlet Obstruction

Opinion of clinician with endoscopic or UGI barium x-ray documentation. Endoscopic evidence would include tight edematous pylorus with an ulcer in the pyloric channel, inability to pass the endoscope tip into the duodenal bulb or descending duodenum, or retained fluid/food in the stomach. UGI barium x-ray evidence of obstruction would include:

- a dilated stomach;
- a slowly emptying stomach in a patient with clinical evidence of outlet obstruction and in some instances with an ulcer in the channel or duodenal bulb; or
- severe narrowing and edema obstructing the outlet of the stomach.

In order to standardize and facilitate the evaluation of suspected GI events in this study, a chart of clinical algorithms is provided as a guide to the work-up of potential events and collection of data necessary to properly classify such events. However, clinical judgement and the administration of standard medical care should take precedence in the evaluation and treatment of all patients in the study over the algorithms detailed in Appendix 1.6.

### **4.5 Other GI Adverse Events**

Data on lower GI adverse events including small bowel or colonic obstruction, ulceration, bleeding, perforation, stricture, colitis, etc. will also be collected and summarized.

Symptomatic UGI ulcers documented by endoscopy or UGI barium x-ray with no evidence of perforation, bleeding or obstruction will be categorized and analyzed separately. Patients with an ulcer must be withdrawn from the study and treated according to the clinical judgment of the investigator.

GI complaints will also be collected and analyzed. Patients who report symptomatic GI adverse events (e.g., abdominal pain, dyspepsia, vomiting) with no endoscopic or UGI barium x-ray evidence of an ulcer may continue to participate in the study at the discretion of the investigator.

Advisory Committee Briefing Document  
February 7, 2000

**4.6 Criteria for Discontinuation**

4.6.a Treatment Failure

Patients who terminate study participation before taking 52 weeks of study medication or the trial officially concludes because their arthritis signs and symptoms have not been controlled will be reported as withdrawing due to "treatment failure".

4.6.b Non-Compliance

Patients who terminate study participation before taking 52 weeks of study medication or before the trial officially concludes due to failure to comply with the requirements of the protocol (e.g., patient fails to take at least 70% of the study medication in any 13 week dispensing interval) will be reported as withdrawing due to "non-compliance".

4.6.c Adverse Events

Patients who terminate study participation before taking 52 weeks of study medication or before the trial officially concludes due to an adverse event (including an ulcer found at an endoscopy; see further definitions in Appendix 1) will be reported as withdrawing due to an "adverse event."

4.6.d Completed Patient

A completed patient is one who takes study medication for 52 weeks or is taking study medication when the trial officially concludes.

**4.7 Withdrawal of a Patient Prior to Study Completion**

If for any reason a patient is withdrawn before completing the study, the reason for withdrawal must be entered on the End of Study Form and Early Termination CRFs must be completed.

**All patients terminating early from the study must be contacted monthly for two months or until the official conclusion of the study, whichever occurs first, to gather pharmaco-economic information as well as to determine if a clinically significant UGI adverse event has occurred. Reasonable attempts must be made to contact each patient.**

# Advisory Committee Briefing Document

## February 7, 2000

### **5.0 STATISTICS**

#### **5.1 Justification of Sample Size**

The null hypothesis being tested is that there is no difference in the incidence of clinically significant UGI adverse events between the SC-58635 and the NSAID group (ibuprofen, naproxen and diclofenac). The log-rank test will be used to detect this difference. The sample size determination is based on the assumption that the probability for experiencing a clinically significant UGI adverse event is 0.3% per year with SC-58635 and 1.2% per year with NSAIDs as a group. To detect this difference with at least 90% power at a 5% significance level (two-sided test) and assuming a withdrawal rate of 35%, a sample size of 8,000 patients (4,000 patients each for the SC-58635 and NSAID group) will be sufficient to obtain approximately a total of 40 clinically significant UGI adverse events. One-half (4000) of the total sample size will be enrolled for this study. The other half of the sample size (4000) will go to a companion study (N49-98-02-102) with naproxen and diclofenac in the NSAID group.

The assumptions about the overall rate of clinically significant UGI adverse events and the withdrawal patterns of patients participating in the study based on the pooled data from each study (N49-98-02-035 and N49-98-02-102) will be reviewed on an ongoing basis during the enrollment period to determine whether an adjustment in the sample size is required. If the incidence rate and withdrawal rate observed are different from the estimations, an adjustment of sample size may be needed to obtain the minimum number of patients exposed to SC-58635 or NSAIDs and to obtain a total of 40 clinically significant UGI adverse events.

### **5.3 Analysis Cohort**

All analyses will be carried out on the Intent-to-Treat cohort. The Intent-to-Treat cohort will consist of all randomized patients from this study and its companion study (N49-98-02-102) who received at least one dose of study medication. Data from this study may also be analyzed independently for exploratory purposes.

### **5.4 Adjudication of Clinically Significant UGI Adverse Events**

A Gastrointestinal Events Committee comprised of expert gastroenterologists, blinded to treatment assignments, will review the data of each patient who is identified by study investigators or Searle as having some evidence of a potentially clinically significant UGI adverse event. The data to be reviewed will include case report forms, and medical records including endoscopy and UGI barium x-ray reports, discharge summaries, and autopsies, where appropriate. The committee will adjudicate whether a clinically significant UGI adverse event has occurred and assign the event to one of the nine classifications (see Section 4.4).

### **5.5 Analysis of Clinically Significant UGI Adverse Events**

Clinically significant UGI adverse events will be descriptively summarized. These analyses will consist of displays of the distribution by treatment group and disease category (i.e., OA or RA) of the number of patients experiencing a clinically significant UGI adverse event (incidence table) and the total number of clinically significant UGI adverse events by classification (frequency table). The primary efficacy analysis will combine results of this study with those from study N49-98-02-102. The active control groups from the two studies will be pooled for this purpose. "Study" will be included as a stratification factor in the analyses.

## Advisory Committee Briefing Document February 7, 2000

Time-to-event analysis will be performed to assess the difference between groups in the clinically significant UGI adverse event rate distribution across time. Clinically significant UGI adverse events occurring within seven days after the start of double-blind treatment will be censored and not included in these analyses. The log-rank test will be used to compare the survival curves of the two treatment groups (SC-58635 vs the NSAID group) with respect to this primary outcome variable. The COX proportional hazards model will be used to estimate the corresponding hazard ratios. Patients who withdrew from the study because of reasons other than incidence of clinically significant UGI adverse events will be censored at the time of withdrawal. Patients who complete the study without a clinically significant UGI adverse event will be censored at the final visit.

The secondary analysis will be a treatment group comparison of the overall proportion of patients with a clinically significant UGI adverse event (crude incidence rate analysis). The Mantel-Haenszel test will be used for these comparisons.

Potential risk factors such as age and history of peptic ulcer, for the development of a clinically significant UGI adverse event will be identified prior to analysis and the proportional hazard model will be used to assess the significance of these factors and their impact on the effect of treatment on outcome.

Disease category (i.e., OA or RA) may be included as a factor in the above analyses.

Symptomatic UGI ulcers documented by endoscopy or UGI barium x-ray with no evidence of perforation, bleeding or obstruction will be categorized and summarized separately.

Clinically significant adverse events occurring in the lower gastrointestinal tract including small bowel or colonic obstruction, ulceration, bleeding, perforation, stricture or colitis will be descriptively summarized. These analyses will consist of displays of the distribution by treatment group and disease category, the number of patients experiencing a clinically significant event in the lower GI tract and the total number of clinically significant lower GI adverse events by classification.

**1.5 CLINICALLY SIGNIFICANT UPPER GASTROINTESTINAL (UGI)  
ADVERSE EVENTS**

If, in the Investigator's opinion, the patient experiences a sign or symptom (e.g., severe abdominal pain, hematemesis, melena, decreased hemoglobin and hematocrit, or severe and protracted nausea and vomiting) that suggests a clinically significant UGI adverse event (i.e., perforation, bleed, or obstruction), the Kendle Safety Specialist must be contacted immediately. All potential clinically significant UGI adverse events will be thoroughly investigated and reported as per following section.

**1.6 ALGORITHM FOR WORK-UP OF SUSPECTED UGI EVENTS**

In order to standardize and facilitate the evaluation of suspected GI events in this study, the following chart of clinical algorithms is provided as a guide to the work-up of potential events and collection of data necessary to properly classify such events. However, clinical judgement and the administration of standard medical care should take precedence in the evaluation and treatment of all patients in the study over the algorithms detailed below.

Advisory Committee Briefing Document  
February 7, 2000

Presentation:	Initial Evaluation:	Work-up
<b>Clinical situations requiring emergent or urgent attention</b> <b>For all patients with the following presentations:</b> <ul style="list-style-type: none"> <li>• Obtain base data (hematocrit, stool heme, and postural vital signs) as part of initial evaluation.</li> <li>• Test for <i>H. pylori</i> infection as part of work-up (Meretek UBT, CLO or H&amp;E).</li> <li>• Notify Searle medical monitor and Kendle Safety Specialist immediately. Provide contact information.</li> <li>• Complete GI event CRF.</li> </ul>		
Severe acute abdominal pain/acute abdomen	<b>EMERGENT:</b> <ul style="list-style-type: none"> <li>• Evaluation for perforating ulcer including base data</li> </ul>	<ul style="list-style-type: none"> <li>• Documentation of perforation by surgery or by laparoscopy with radiographic evidence of free air in abdomen</li> <li>• Test for <i>H. pylori</i> infection</li> </ul>
Intractable abdominal pain with nausea/vomiting	<b>EMERGENT:</b> <ul style="list-style-type: none"> <li>• Evaluation for gastric outlet obstruction including base data</li> </ul>	<ul style="list-style-type: none"> <li>• Documentation of gastric outlet obstruction with UGI study (radiographic or endoscopic)</li> <li>• Test for <i>H. pylori</i> infection</li> </ul>
Hematemesis or melena	<b>EMERGENT:</b> <ul style="list-style-type: none"> <li>• Evaluation for GI bleeding source including base data</li> </ul>	<ul style="list-style-type: none"> <li>• Documentation of bleeding source by UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>
Acute hypovolemia/hypotension	<b>EMERGENT:</b> <ul style="list-style-type: none"> <li>• Evaluation for acute GI blood loss including base data</li> </ul>	<ul style="list-style-type: none"> <li>• If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>
Current/recent (<14 days) history of: <ul style="list-style-type: none"> <li>• melena (black tarry stool) or</li> <li>• black stool which is a change in normal pattern</li> </ul>	<b>IMMEDIATE:</b> <ul style="list-style-type: none"> <li>• Obtain base data</li> </ul>	<ul style="list-style-type: none"> <li>• If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> <li>• If work-up negative, retest stool for heme and repeat hematocrit in 1-2 weeks</li> </ul>
Development of: <ul style="list-style-type: none"> <li>• postural dizziness or lightheadedness</li> <li>• syncope</li> </ul>	<b>IMMEDIATE:</b> <ul style="list-style-type: none"> <li>• Obtain base data</li> <li>• If patient orthostatic, evaluate for acute GI blood loss</li> </ul>	<ul style="list-style-type: none"> <li>• If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>

Advisory Committee Briefing Document  
February 7, 2000

Presentation:	Initial Evaluation:	Work-up
<b>Clinical situations requiring prompt attention:</b> For all patients with the following presentations: <ul style="list-style-type: none"> <li>• Obtain base data (hematocrit, stool heme x3, and postural vital signs) as soon as possible.</li> <li>• Test for <i>H. pylori</i> infection as part of work up (Meretek UBT, CLO or H&amp;E)</li> <li>• Notify Kendle Safety Specialist as soon as possible.</li> <li>• Complete GI event CRF.</li> </ul>		
History of dark stool: <ul style="list-style-type: none"> <li>• &gt;14 days previously, or</li> <li>• vaguely characterized, or</li> <li>• with concurrent iron/bismuth ingestion</li> </ul>	ASAP: <ul style="list-style-type: none"> <li>• Obtain base data</li> </ul>	<ul style="list-style-type: none"> <li>• If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>
History of : <ul style="list-style-type: none"> <li>• hematochezia, or</li> <li>• anal/rectal bleeding after elimination</li> </ul>	ASAP: <ul style="list-style-type: none"> <li>• Obtain base data</li> </ul>	<ul style="list-style-type: none"> <li>• Perform colonoscopy</li> <li>• UGI endoscopy at Investigator's discretion (test for <i>H. pylori</i> infection)</li> </ul>
Development of: <ul style="list-style-type: none"> <li>• New anemia, or</li> <li>• Drop in hematocrit of 5% or more (absolute change)</li> </ul>	ASAP: <ul style="list-style-type: none"> <li>• Obtain base data</li> </ul>	<ul style="list-style-type: none"> <li>• If stools heme positive, perform UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>
Development of: <ul style="list-style-type: none"> <li>• Dyspepsia, or</li> <li>• Abdominal pain, or</li> <li>• Nausea/vomiting</li> </ul>	ASAP: <ul style="list-style-type: none"> <li>• Obtain base data</li> </ul>	<ul style="list-style-type: none"> <li>• If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection)</li> <li>• Colonoscopy at Investigator's discretion</li> </ul>

## *Important Protocol amendments*

### November 9<sup>th</sup> 1998

#### **PROTOCOL SECTION AMENDED**

Abstract, 4th and 6th paragraphs, page 3 of 35

This randomized, double-blind, parallel group, multicenter study is designed to compare the incidence of clinically significant UGI adverse events associated with SC-58635 400 mg BID to that associated with ibuprofen 800 mg TID in patients with osteoarthritis (OA) or rheumatoid arthritis (RA). Clinically significant UGI adverse events is a composite safety endpoint comprised of perforation, bleeding or gastric outlet obstruction. The primary analysis of this study will consist of a survival analysis of the UGI adverse events in this study pooled with those of a companion study (N49-98-02-102). The primary

Advisory Committee Briefing Document  
February 7, 2000

comparison will be the incidence of clinically significant UGI adverse events associated with SC-58635 400 mg BID to that associated with NSAID treatment consisting of ibuprofen 800 mg TID, ~~naproxen 500 mg BID~~ and separately to that associated with ~~or~~ diclofenac 75 mg BID.

Patients who meet all of the inclusion/exclusion criteria for the study will be randomized to receive SC-58635 400 mg BID or ibuprofen 800 mg TID. Follow-up visits will occur 4, 13, 26, 39 and 52 weeks after the first dose of study medication. The trial will continue until the anticipated number of clinically significant UGI adverse events have been observed in both studies. **Minimum study participation for an individual patient is 26 weeks and** maximum study participation for an individual patient is 52 weeks. All patients will complete a Final Treatment visit which may coincide with the Week 52 visit or occur at any time up to Week 52 when the trial officially concludes. Patients who withdraw early from the trial will be contacted by phone monthly for two months.

#### PROTOCOL SECTION AMENDED

##### 5.1 Justification of Sample Size, 1st paragraph, page 27 of 35

~~The null hypothesis being tested is that there is no difference in the incidence of clinically significant UGI adverse events between the SC-58635 and the NSAID group (ibuprofen, naproxen and diclofenac). The log-rank test will be used to detect this difference. The sample size determination is based on the assumption that the probability for experiencing a clinically significant UGI adverse event is 0.3% per year with SC-58635 and 1.2% per year with NSAIDs as a group. To detect this difference with at least 90% power at a 5% significance level (two-sided test) and assuming a withdrawal rate of 35%, a sample size of 8,000 patients (4,000 patients each for the SC-58635 and NSAID group) will be sufficient to obtain approximately a total of 40 clinically significant UGI adverse events. One half (4000) of the total sample size will be enrolled for this study. The other half of the sample size (4000) will go to a companion study (N49-98-02-102) with naproxen and diclofenac in the NSAID group.~~

##### 2nd paragraph, page 27 of 35

~~The assumptions about the overall rate of clinically significant UGI adverse events and the withdrawal patterns of patients participating in the study based on the pooled data from each study (N49-98-02-035 and N49-98-02-102) will be reviewed on an ongoing basis during the enrollment period to determine whether an adjustment in the sample size is required. If the incidence rate and withdrawal rate observed are different from the~~

Advisory Committee Briefing Document  
February 7, 2000

~~estimations, an adjustment of sample size may be needed to obtain the minimum number of patients exposed to SC-58635 or NSAIDs and to obtain a total of 40 clinically significant UGI adverse events.~~

**The statistical analyses will be performed on the data from this study and its companion study. The patients on celecoxib will be pooled as one group (N49-98-02-035 and N49-98-02-102) while the patients on NSAIDs will remain as separate. The sample size calculation is based on the pairwise comparison of pooled celecoxib and each of the NSAIDs.**

**The null hypothesis being tested is that there is no difference in the incidence of clinically significant UGI adverse events between the SC-58635 group and each of the NSAID groups (ibuprofen and diclofenac). The log-rank test will be used to detect the difference by pairwise comparisons. The sample size determination is based on the assumption that the probability for experiencing a clinically significant UGI adverse events is 0.3% per year with SC-58635 and 1.2% per year with each NSAID group. With approximately 85% power at a 5% significance level (two-sided test) and assuming a withdrawal rate of 35%, a sample size of 4,000 patients (combining the two studies) for the SC-58635 group and 2,000 for each of the NSAID groups would be needed. A total number of 40 events will be expected (8 from the combined SC-58635 group and 16 from each NSAID group). The enrollment is designed to take about three months and the follow-up will be at least six months. The studies will be concluded with at least 20 events from each of the studies or a total of 45 events from the two studies.**

Advisory Committee Briefing Document  
February 7, 2000

1.6 ALGORITHM FOR WORK-UP OF SUSPECTED UGI EVENTS, pages 5 and 6 of 6

Presentation:	Initial Evaluation:	Work-up
<b>Clinical situations requiring emergent or urgent attention</b> For all patients with the following presentations: <ul style="list-style-type: none"> <li>• Obtain base data (hematocrit, stool heme, and postural vital signs) as part of initial evaluation.</li> <li>• Test for <i>H. pylori</i> infection as part of work-up (Meretek UBT, CLO or H&amp;E).</li> <li>• Notify Searle medical monitor and Kendle Safety Specialist immediately. Provide contact information.</li> <li>• Complete GI event CRF.</li> </ul>		
Severe acute abdominal pain/acute abdomen	EMERGENT: Evaluation for perforating ulcer including base data	Documentation of perforation by surgery or by laparoscopy with radiographic evidence of free air in abdomen Test for <i>H. pylori</i> infection
Intractable abdominal pain with nausea/vomiting	EMERGENT: Evaluation for gastric outlet obstruction including base data	Documentation of gastric outlet obstruction with UGI study (radiographic or endoscopic) Test for <i>H. pylori</i> infection
Hematemesis or melena	EMERGENT: Evaluation for GI bleeding source including base data	Documentation of bleeding source by UGI endoscopy (test for <i>H. pylori</i> infection) <del>Colonoscopy at Investigator's discretion</del> <b>Lower GI workup if bleeding source uncertain</b>
Acute hypovolemia/hypotension	EMERGENT: Evaluation for acute GI blood loss including base data	If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection) <del>Colonoscopy at Investigator's discretion</del> <b>Lower GI workup if bleeding source uncertain</b>
Current/recent (<14 days) history of: melena (black tarry stool) or black stool which is a change in normal pattern	IMMEDIATE: Obtain base data	If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection) <del>Colonoscopy at Investigator's discretion</del> <b>Lower GI workup if bleeding source uncertain</b> If work-up negative, retest stool for heme and repeat hematocrit in 1-2 weeks
Development of: postural dizziness or lightheadedness syncope	IMMEDIATE: Obtain base data If patient orthostatic, evaluate for acute GI blood loss	If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection) <del>Colonoscopy at Investigator's discretion</del> <b>Lower GI workup if bleeding source uncertain</b>

**Two primary treatment comparisons will be performed: celecoxib vs. ibuprofen and celecoxib vs. diclofenac. A stepwise procedure will be used to strongly control the type-I error. In this procedure, the first step is to test the overall hypothesis whether celecoxib and the pooled NSAIDs are different. If the test is not significant, the null hypothesis is retained and the procedure stops. If the test is significant, the second step will be the pairwise tests between celecoxib and each of the two NSAIDs. Celecoxib will be said to be different from an NSAID if both overall and pairwise comparisons of celecoxib vs that NSAID are significant. Each test will be performed at level alpha. No alpha adjustment is needed for each test. (See Appendix 6 for a statistical proof)**

**Two endpoints will be analyzed. One is based on the traditional definition and the**

Advisory Committee Briefing Document  
February 7, 2000

1.6 ALGORITHM FOR WORK-UP OF SUSPECTED UGI EVENTS, pages 5 and 6 of 6

Presentation:	Initial Evaluation:	Work-up
<p><b>Clinical situations requiring emergent or urgent attention</b>            For all patients with the following presentations:</p> <ul style="list-style-type: none"> <li>• Obtain base data (hematocrit, stool heme, and postural vital signs) as part of initial evaluation.</li> <li>• Test for <i>H. pylori</i> infection as part of work-up (Meretek UBT, CLO or H&amp;E).</li> <li>• Notify Searle medical monitor and Kendle Safety Specialist immediately. Provide contact information.</li> <li>• Complete GI event CRF.</li> </ul>		
Severe acute abdominal pain/acute abdomen	EMERGENT: Evaluation for perforating ulcer including base data	Documentation of perforation by surgery or by laparoscopy with radiographic evidence of free air in abdomen Test for <i>H. pylori</i> infection
Intractable abdominal pain with nausea/vomiting	EMERGENT: Evaluation for gastric outlet obstruction including base data	Documentation of gastric outlet obstruction with UGI study (radiographic or endoscopic) Test for <i>H. pylori</i> infection
Hematemesis or melena	EMERGENT: Evaluation for GI bleeding source including base data	Documentation of bleeding source by UGI endoscopy (test for <i>H. pylori</i> infection) <b>Colonoscopy at Investigator's discretion</b> <b>Lower GI workup if bleeding source uncertain</b>
Acute hypovolemia/hypotension	EMERGENT: Evaluation for acute GI blood loss including base data	If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection) <b>Colonoscopy at Investigator's discretion</b> <b>Lower GI workup if bleeding source uncertain</b>
Current/recent (<14 days) history of: melena (black tarry stool) or black stool which is a change in normal pattern	IMMEDIATE: Obtain base data	If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection) <b>Colonoscopy at Investigator's discretion</b> <b>Lower GI workup if bleeding source uncertain</b> If work-up negative, retest stool for heme and repeat hematocrit in 1-2 weeks
Development of: postural dizziness or lightheadedness syncope	IMMEDIATE: Obtain base data If patient orthostatic, evaluate for acute GI blood loss	If GI evaluation positive (e.g., blood in NG aspirate, heme positive stool, or hematocrit decreased by 5% or more [absolute change]), investigate source with UGI endoscopy (test for <i>H. pylori</i> infection) <b>Colonoscopy at Investigator's discretion</b> <b>Lower GI workup if bleeding source uncertain</b>

Advisory Committee Briefing Document  
February 7, 2000

Presentation:	Initial Evaluation:	Work-up
<p><b>Clinical situations requiring prompt attention:</b> For all patients with the following presentations:</p> <ul style="list-style-type: none"> <li>• Obtain base data (hematocrit, stool heme x3, and postural vital signs) as soon as possible.</li> <li>• Test for <i>H. pylori</i> infection as part of work up (Meretek UBT, CLO or H&amp;E)</li> <li>• Notify Kendle Safety Specialist as soon as possible.</li> <li>• Complete GI event CRF.</li> </ul>		
History of dark stool: >14 days previously, or vaguely characterized, or with concurrent iron/bismuth ingestion	ASAP: Obtain base data	If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection) Colonoscopy at Investigator's discretion <b>Lower GI workup if bleeding source uncertain</b>
History of : hematochezia, or anal/rectal bleeding after elimination	ASAP: Obtain base data	Perform colonoscopy UGI endoscopy at Investigator's discretion (test for <i>H. pylori</i> infection)
Development of: New anemia, or Drop in hematocrit of 5% or more (absolute change)	ASAP: Obtain base data <b>including ferritin, iron, iron binding capacity, MCV, MCHC</b>	If stools heme positive <b>or studies indicate iron deficiency</b> , perform UGI endoscopy (test for <i>H. pylori</i> infection) Colonoscopy at Investigator's discretion <b>Lower GI workup if bleeding source uncertain</b>
Development of: Dyspepsia, or Abdominal pain, or Nausea/vomiting	ASAP: Obtain base data	If any component of work-up positive (stool heme positive, hematocrit decreased by 5% or more [absolute change], or patient orthostatic), perform UGI endoscopy (test for <i>H. pylori</i> infection) Colonoscopy at Investigator's discretion <b>Additional studies as indicated by "ordinary care"</b>
Development of: <b>Heme-positive stools</b>	ASAP: Obtain base data	<b>Perform UGI endoscopy (test for <i>H. pylori</i> infection)</b> <b>Lower GI workup if bleeding source uncertain</b>

NEW APPENDIX ADDED

**Appendix 6. Additional Statistical Procedures**

**Justification of the Stepwise Procedure:**

The strong control of type-I error using this method can be proved by closed testing procedure setup or by direct calculation as following:

$H_0$ :  $H_{01}$  rate of celecoxib = rate of ibuprofen,  
 $H_{02}$  rate of celecoxib = rate of diclofenac.

By definition, we need to prove that the type-I error is controlled under any configuration of the null hypothesis. In our case, we need to prove that for each  $H_{01}$ ,  $H_{02}$  and  $H_0$ . The demonstration for the cases of  $H_{01}$  and  $H_{02}$  are straightforward. The probability of rejecting  $H_{01}$  or  $H_{02}$  when  $H_0$  is true can be seen by the following expression:

$$\begin{aligned} & P(\text{reject } H_{01} \text{ or reject } H_{02} \mid H_{01} \text{ and } H_{02} \text{ true}) = \\ & P(\text{reject overall first and (reject } H_{01} \text{ or reject } H_{02} \text{ pairwise)} \mid H_{01} \text{ and } H_{02} \text{ true}) = \\ & P(\text{reject overall} \mid H_{01} \text{ and } H_{02} \text{ true}) \times \\ & P(\text{reject } H_{01} \text{ or } H_{02} \text{ pairwise} \mid H_{01} \text{ and } H_{02} \text{ true and overall rejected}) \leq \\ & P(\text{reject overall} \mid H_{01} \text{ and } H_{02} \text{ true}) \\ & = 0.05 \end{aligned}$$

Hence the result.

## **Amendment November 24<sup>th</sup> 1999**

### **REASON FOR ADMINISTRATIVE CHANGE**

1. To change and further clarify the censoring rules for clinically significant UGI adverse events.

Protocol section(s) corrected and details of the changes are as follows:

### **PROTOCOL SECTION CORRECTED:**

5.5 Analysis of Clinically Significant UGI Adverse Events, 2nd Paragraph, page 29 of 35

Time-to-event analysis will be performed to assess the difference between groups in the clinically significant UGI adverse event rate distribution across time. ~~Clinically-significant UGI adverse events occurring within seven days after the start of double-blind treatment will be censored and not included in these analyses.~~ **All clinically significant UGI adverse events which occur after 48 hours following the first dosing day and before 48 hours following the last dosing day will be included in the analysis. In addition, the Gastrointestinal Events Committee will review potential clinically significant UGI adverse events which occur after the back-end censoring cut-off date. If such adverse events are deemed to be clinically significant UGI adverse events, occur within 2 weeks of the last study drug dose, and are felt to be study drug related, they will also be included. These rules thus exclude only clinically significant adverse events which occur within 48-72 hours after initiation of study drug (which are not reasonably attributable to study drug) or clinically significant adverse events which occur after the cessation of study drug where another cause of the clinically significant adverse event is evident (e.g., resumption of NSAID use) or where sufficient time has elapsed to call causality into question (2 weeks).** The log-rank test will be used to compare the survival curves of the two treatment groups (celecoxib vs ibuprofen and celecoxib vs diclofenac) with respect to this primary outcome variable. The COX proportional hazards model will be used to estimate the corresponding hazard ratios. Patients who withdrew from the study because of reasons other than incidence of clinically significant UGI adverse events will be censored at the time of withdrawal. Patients who complete the study without a clinically significant UGI adverse event will be censored at the final visit.

## References

1. Wollheim FA, Selective Cox-2 inhibition in man-therapeutic breakthrough or cosmetic advance? *Rheumatology*, 2000; 39:935-38
2. Wolfe MM Lichtenstein DR and Singh G, Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, *NEJM*. 1999; 340:1888-99
3. Singh G. ,Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997 *J Rheumatol* 1998; 25 Suppl 51:8-16
4. Garcia LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs *Lancet* 1994; 343: 769-72
5. Henry D et al. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. *Gastro* 1993; 105: 1078-1088
6. Garcia Rodriguez LA Nonsteroidal anti-inflammatory drugs, ulcers and risk: A collaborative meta-analysis *Semin Arthritis Rheum* 1997; 26; 16-20
7. Gabriel SE. et al. Risks for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs 1991 *Ann Intern Med*. 115:787-96
8. Singh G et al. Comparative toxicity of non-steroidal anti-inflammatory agents. *Pharmac Ther*. 1994: 62;175-91
9. Perez Gutthaus S et al. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation *Epidemiology* 1997; 8;18-24
10. Pounder R. Silent peptic ulceration: deadly silence or golden silence? *Gastro*: 1989; 96:626-31

Advisory Committee Briefing Document  
February 7, 2000